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B cells are critical for the generation of antibody, but there is increasing evidence that they 
have a broader functional remit: For example, innate B1a cells are a critical source of 
granulocyte macrophage colony-stimulating factor (GM-CSF) during Gram-negative sepsis, 
inducing neutrophil expansion and mobilisation to limit bacteraemia. B cells can also regulate 
immune responses via the production of cytokines such as IL-10, and this can inhibit 
deleterious autoimmune and alloimmune responses in murine models. 
Here I investigated whether B cells may play a pathogenic role in the sterile 
inflammation associated with acute kidney injury (AKI), coordinating a systemic response in 
which neutrophils and inflammatory monocytes are mobilised from the bone marrow to the 
injured kidney.  We found that during murine models of AKI, neutrophils exit the bone 
marrow and increase in the blood and kidneys. This neutrophil mobilisation was tightly 
correlated to the severity of AKI. B cells were recruited to the kidney in a CD11b-dependent 
manner and produced CCL7 to attract inflammatory monocytes.  The absence of Siglec-G, an 
inhibitory receptor expressed in innate B1a cells, exacerbates AKI in murine models. 
Conversely, concomitant administration of a Siglec-G agonist, sialic acid (Neu5AC), 
ameliorated AKI and reduced renal neutrophil infiltration. These data suggest that 




In the second part of the thesis, I investigated whether IL-10-producing regulatory B 
cells could be induced in humans in vivo. Transcriptomic analysis demonstrated that IL-10-
producing human B cells expressed transcripts of all components of the IL-2 receptor (CD25, 
CD122 and CD132). We found that surface CD25 was upregulated on a subset of mouse and 
human B cells following stimulation with toll-like receptor (TLR) agonists and CD40L, 
rendering these cells receptive to IL-2. The addition of IL-2 to these activated B cells 
significantly augmented IL-10 production, whilst pro-inflammatory cytokines such as IL-6 and 
tumour necrosis factor alpha (TNF-α) were unchanged, resulting in a skewing of B cells 
towards a regulatory phenotype. Consequently, co-culture of IL-2-treated B cells with 
activated CD4 cells led to a reduction in T cell production of TNF-α. In vivo, in mice and 
patients treated with low dose IL-2, we observed a significant increase in IL-10-producing B 
cells. Together, our data suggest that low dose IL-2 may be a useful strategy to promote the 
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To contextualise current efforts to understand the role of B cells and plasma cells in immune 
responses and disease, it is worth considering the scientific work of the both named and 
anonymous pioneers in the field of B cell biology particularly over the past 150 years. 
Contrary to the timelines of discoveries that imply a clean linear historical narrative, even 
casual investigation of the discovery of B cells reveals a story full of unintended diversions 
which plot a meandering path to scientific knowledge. Though within an experimental 
medical doctoral thesis a rigorous and original history derived from primary sources is 
unfeasible, a less ambitious epistemological exercise considering how different forces shaped 
the early scientific knowledge about B cells may provide perspective on how we as research 
immunologists approach our work today.  
The early history of B cells is defined as the history leading up to three major 
discoveries: the identification of B cells, the identification of plasma cells and the isolation of 
antibodies. The history presented here, is how an understanding of the functions of B cells – 
and not the B cell in and of itself – was propelled by the search for antitoxins or antibodies 
that could be life-saving during an infection. The identification of the B cell was a secondary 
priority. Even after speculation that B cells existed in the early twentieth century, there is no 
evidence that a concerted effort to search for the antibody’s source ever existed. Indeed, I 
show that in order for the discovery of B cells to take place, it was necessary for the 




one in which science could be conducted in order to provide a better understanding of the 
basic tenets of biology.  
 
1.1 Inoculation and the early history of B cells 
While there is a rich history of the study of immunisation and therefore a study of the 
functional consequence of B cells before the nineteenth century, these discoveries will be 
only briefly considered here. Smallpox, a disease which has at least a 16,000 year-long history 
was by the 18th century killing 400,000 Europeans annually (Esposito, et al. 2006) (Hays 2005).  
 
    
 
 Figure 1.1 (left): Bust of Thucydides, Louvre Museum, Paris, France (Artist and 
date of artwork unknown). Figure 1.2 (right). Plague of Athens (as reimagined 
in the 17th century) by Michiel Sweerts (1618-1664) (The Plague of Athens, 
Michiel Sweerts 1652-1654).  
 
A preventative treatment for the disease was documented as early as 429 BCE, by the 
Athenian historian and general Thucydides (circa 460-400 BCE, figure 1.1) who noted in his 
book, History of the Peloponnesian War, that during the Plague of Athens (430-427 BCE, 
figures 1.2 and 1.3) those Athenians who survived the disease once were unlikely to acquire 






“Yet it was with those who had recovered from the disease that the sick and 
the dying found most compassion. These knew what it was from experience, 
and had now no fear for themselves; for the same man was never attacked 
twice- never at least fatally. And such persons not only received the 
congratulations of others, but themselves also, in the elation of the moment, 
half entertained the vain hope that they were for the future safe from any 
disease whatsoever.” (Thucydides 431 BCE) 
 
Subsequently, a more directed therapy called variolation was developed. Variolation derives 
its name from the variola family of viruses which contains the smallpox virus.  This inoculation 
which involved either exposing skin to scabs or insufflating scabs from smallpox patients 
became widely practiced from about 1000 AD first in India and subsequently in China, 
Western Asia and Africa (Macgowan 1884) (Needham 1980). The practice eventually reached 
Europe and North America in the 18th century. In England, Mary Wortley Montagu (1689-
1762) reputedly imported variolation following her family’s diplomatic deployment to 
Constatinople. A development on this was illustrated by Edward Jenner (1749-1823, figure 
1.3) along with a number of other lesser known contemporaries such as Jobst Bose in 
Göttingen, Germany, Benjamin Jesty (circa 1736-1816 ) in Dorset, England and others who 
noted that exposure to cowpox, which gives a relatively mild viral disease in humans, 







 Figure 1.3. Edward Jenner conducting experiments into smallpox. (Artist and 
date of artwork unknown).  
 
1.2 Speculation on the existence of B cells 
It is possible, perhaps somewhat arbitrarily, to demarcate the formal start of the search for B 
cells with the genesis of the documented idea of a B cell which was posited as early as 1908 
by Paul Ehrlich (1854-1915). At the end of the nineteenth century, the German physician Emil 
von Behring (1854-1917, figure 1.4) and the Japanese physician Kitasato Shibasaburō (1853-
1931) hypothesized the existence of ‘antitoxin,’ or what later became known as antibodies in 
response to bodily exposure to filtrates of diphtheria culture containing no bacterial cells. 
Ehrlich went on to hypothesize in his Nobel lecture “ . . . I believe that I may now pronounce 
it as a definite fact that certain specific groupings must in fact exist in the cells which fix the 




Figure 1.4: Emil von Behring (far right) experimenting with immunisation of a 
horse (Artist unknown 1894).  
 
1.3 Early developments in antibodies 
Arne Tiselius (1902-1971), a Swedish biochemist, initially developed the technique of protein 
electrophoresis in a buffer in 1930 and subsequently with his colleague Elvin A Kabat (1914-




immunonoglobulins (Black 1997) (Tiselius and Kabat 1939). This was the first antibody to be 
isolated.  
 
1.4 Identification of B cells 
First described by Hieronymus Fabricius (1537-1619) of Padua, the Bursa of Fabricius, is an 
outpouching of the proctodaeum, which is located in the back ectodermal segment of the 
alimentary canal of a hen (figures 1.5 and 1.6). The function of this bursa was not completely 
clear at that time.  
 
    
 
Figure 1.5 (left). Engraving of Hieronymus Fabricius (Artist and date of artwork 
unknown). Figure 1.6 (right). Diagram of position of bursa of Fabricius 
(Sivakumar 2018). 
 
 Little progress was made on the function of this structure, though some hypothesized 
an endocrine function (Perek and Eilat 1960) (Newcomer and Connally 1960). Almost four 
centuries after Fabricius’s initial descriptions, in 1956, a post-graduate student named Bruce 
Glick (1927-2009, figure 1.7) at the University of Ohio surgically removed the bursa of newly-
hatched white leghorn chicks to investigate their phenotype. Crucially, the decision to do so 
was not based on a strong hypothesis of the function of the structure. There was no evidence 
of suspicion the organ was responsible for antibody production. When Glick observed no 
outward differences, he returned the birds to the farm where Timothy Scott Chang (1925-
2011, figure 1.8) another student from the same laboratory used them along with other non-
Anus 






bursectomised hens for an immunisation demonstration with salmonella-type O. A number 
of bursectomised birds died and the blood of the surviving birds showed no agglutination 
which would have been suggestive of effective immunisation. Disappointment was followed 
by the realisation that cells within the bursa may be responsible for antibody production.  
 
     
 
 Figure 1.7 (left). Bruce Glick pictured with the subject of his life-long research 
(Kincade 2003). Figure 1.8 (middle). Timothy Scott Chang (American 
Association of Avian Pathologists 2018). Figure 1.9 (right). George Japp 
(American Poultry Historical Society, Inc. 2013). 
 
With excitement, Glick and Chang’s supervisor, George Jaap (1905-1992, figure 1.9) 
suggested the work, “The Role of the Bursa of Fabricius in Antibody Production” be 
submitted to the journal Science. The article was turned down because of the lack of 
mechanistic understanding (Davison 2012) (Glick 1987). Eventually the work was published in 
Poultry Science where it remained largely forgotten until the mid-1960s when there was an 
acceleration in interest in antibody biochemistry (Glick, Chang and Jaap 1956).  
 Glick and Chang’s discovery was fortuitous because gallinaceous birds such as 
chickens, turkeys, pheasants, grouse, partridges, and quails have a discrete organ which 
contains the majority of their B cell population. Such a discovery would not have been 
possible in mammals such as mice in which migratory B cells are scattered in the bone 





1.5 Identification of plasma cells  
Astrid Fagraeus (1913-1997, figure 1.10) observed the histological features of a rabbit spleen 
before and after antigen immunisation. The changes were subtle but the increase of plasma 
cells in the red pulp suggested these cells may be the source of antibodies (Fagraeus 1948). 
In vitro assays measuring supernatant immunoglobulins of carefully dissected splenic tissue 
suggested the red pulp to indeed be the source of antibodies. Subsequently, antibody 
production was confirmed in these cells in one of the first descriptions of immunofluorescent 
microscopy (figure 1.11) (Coons, Leduc and Connolly 1955). 
 
 A  B  
 
Figure 1.10 (left). A. Astrid Fagraeus (Norberg, Biberfeld and Wigzell 1998). 
Figure 1.11 (right). Originally published microscopy image image of “Rabbit . . . 
Spleen. Stained for anti-human γ-globulin. Higher power of similar islands of 
cells in the red pulp. X 560” (Coons, Leduc and Connolly 1955). 
 
1.6 Current understanding of the development of B cells 
Following these early discoveries, the developments in understanding of B cells have 
accelerated greatly since the 1960s. Presented here is a basic review of our understanding of 
B cells largely from a developmental perspective. For further historical perspectives of more 
recent discoveries, see Edward Moticka’s A Historical Perspective on Evidence-Based 
Immunology (Moticka 2015).  
B cells, also known as B lymphocytes, are a type of white blood cell which develop in 




cells with a lymphoid lineage include T cells, natural killer cells and innate lymphoid cells. B 
cells, unlike other lymphoid cells however, are unique in their expression of a B cell receptor 
(BCR), a surface bound antibody (Ab) or immunoglobulin (Ig). In addition to the BCR, B cells 
also transiently express a range of surface markers such as CD10, CD19, CD20, CD25, and 
B220 which reflect the cell’s developmental stage, activation status and function (Tables 1.1 
and 1.2). The primary function of a B cell has been defined as a precursor to Ab-producing 
plasma cells. However, as explored later, this perception of B cells has undergone revision 
lately given the wide range of additional functions that B cells also exhibit. 
 
Tables 1.1 and 1.2 (over the next two pages). Human and murine B cell surface 
markers during development. Where I have found no evidence of a surface 
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1.7 B cell development in the bone marrow 
Stages of B cell development have traditionally been aligned to stages of recombination of 
the BCR gene and therefore it is appropriate to briefly discuss Ig before describing B cell 
development. Ig consist of two heavy chains and two light chains. Heavy chains are 
transcribed from genes independent of light chains which are transcribed from either kappa 
(κ) or lambda (λ) genes. The heavy chain is transcribed from three gene regions: the variable 
(V) region, the diversity (D) region and the joining (J) region. The nature of the heavy chain 
determines antibody isotype (figure 1.12). For example, a µ heavy chain is associated with 
IgM while a γ heavy chain is associated with IgG. The light chain consists of two gene regions: 
the V and J regions which can either be kappa or lambda. In humans, there are 65 different 
heavy chain V gene segments, 27 heavy chain D segments and 6 joining heavy chain J 
segments (figure 1.14). Multiple gene segments encoding for the light chain also exist.  
 
 
Figure 1.12: The type of heavy chain determines the antibody isotype.  
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Figure 1.13. Stages of B cell development in the bone marrow. B cells arise 
from common lymphoid progenitors and proceed through a series of distinct 






















IL-7Rα Pre-B cell µ heavy chain made 
Immature B cell Y 
Light chain rearranged 
λ and κ chain made 
Surface IgM expressed 
IgM 
µ 
B cells leave bone marrow for 




as mature naïve B cells and circulate in the blood to spleen and lymph nodes. 
Figure modified from (Parnham 2014). 
 
  
Figure 1.14: Variable, diversity, joining and constant regions of heavy and light 
chains. Figure modified from (Parnham 2014).  
 
Rearrangements of genetic material encoding the V, D and J regions of the heavy 
chain are called VDJ recombination (figure 1.14). The first recombination to take place is 
between the D and J regions followed by the V region. Non-relevant V, D and J regions are 
deleted from the genome during this process.  Subsequently, an equivalent V-J 
recombination of the light chain genes also takes place. The light chain does not have a D 
domain. The genes are transcribed and the assembly of the heavy and lights chains takes 
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Figure 1.15: Schematic diagram of VDJ recombination when gene segment are 
randomly assembled during the pro-B cell phase. Figure modified from 
(Parnham 2014).  
 
In most mammals, including mice and humans, B cells originate in the bone marrow. 
Here, pluripotent haematopoietic stem cells develop, in chronological order, into a common 
lymphoid progenitor, a B cell precursor and eventually a pro-B cell when rearrangements of 
genes encoding for the heavy chain of Ig take place (figure 1.15). Following the pro-B cell 
phase, the pre-B cell phase consists of the large pre-B cell phase, when µ heavy chains are 
first made, and the latter small pre-B cell phase when VJ rearrangement of the light chain 
genes first take place. The final stage of development in the bone marrow is the immature B 
cell phase when genes for the light chains κ and λ are rearranged and made. During this 
phase light and heavy chain proteins are made and it is possible for the first time to 
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1.8 B cell maturation 
Immature B cells leave the bone marrow via the bloodstream and arrive in the spleen for 
further maturation. During the transit from the marrow to the spleen, B cells are termed 
transitional 1 (T1) B cells and express high levels of CD24 and CD38 in humans and CD21 and 
23 in mice. Engagement of the BCR induces apoptosis during this time. Once in the spleen, 
BAFF signalling (B cell activating factor belonging to the tumour necrosis factor family) 
induces B cells to develop from a T1 phenotype to a T2 phenotype. T2 cells go on to 
differentiate in follicles into circulating follicular B cells or into non-circulating B cells in the 
marginal zone (MZ). Within the follicles, follicular dendritic cells (FDC) are crucial in retaining 
B cells through production of B cell lymphocyte chemoattractant (BLC), also known as C-X-C 
motif ligand 13 (CXCL13). Upon exposure to antigen, follicular B cells can migrate to the 
follicular borders and present peptides to T cells in the context of MHC. In return, B cells are 
also stimulated through CD40 upon receipt of T cell help. B cells return to the follicle to form 
a germinal centre (GC) within which B cells undergo somatic hypermutation in an attempt to 
produce antibody with a higher affinity for antigen (Di Noia and Neuberger 2007). They also 
undergo class switching, so that the heavy chain present in antibody changes from μ to one 
of the other isotypes.  During many rounds of division and hypermutation, B cells with a high 
affinity BCR are positively selected and differentiate into either memory B cells or plasma 
cells (Goodnow, et al. 2010). A subset of CD4 T cells, known as T follicular helper (Tfh) cells, 
are engaged by GC B cells presenting antigen to them. This Tfh-B cell interaction is essential 
for the progress of the GC reaction and for the development of memory B cells and plasma 
cells (Vinuesa, et al. 2010).  
Only a small proportion of plasma cells arising from the GC become established as 
long-lived plasma cells in the bone marrow. They reside within a number of limited niches, do 
not proliferate, but act as long-term antibody factories, producing IgG (Nutt, et al. 2015). 
Plasma cells have also been described in inflamed tissues in autoimmunity and within 






1.9 B1 cells 
Conventional B cells, which we have discussed in previous paragraphs are classified as B2 
cells. Another distinct category of B cells, B1 cells, was first described in leukemic cells where 
it was noted that some B cells expressed CD5, a protein more commonly expressed in T cells 
(Lanier, et al. 1981) (Wang, et al. 1980). Subsequently, CD5 expression was found on normal 
B cells (Hardy, et al. 1982) (Manohar, et al. 1982). While B1 cells are found to reside in the 
peritoneal cavity, pleural cavity, spleen and bone marrow under normal circumstances, their 
origin remains controversial (Hayakawa, Hardy and Herzenberg 1986) (Hayakawa, Hardy and 
Parks, et al. 1983). Adoptive transfer of bone marrow cells does not replenish B1 cells in the 
peritoneum whereas fetal liver cells do. These experiments have not convincingly answered 
exactly the specific fetal liver cell type which gives rise to the B1 cell population (Kantor, et al. 
1992). There has also been suggestion that B1 cells arise from the yolk sac and para-aortic 
splanchnopleural tissues (Yoshimoto et al., 2011). Finally, complicating this question has been 
the suggestion that B2 cells can be induced to take on more B1 cell characteristics (Berland 
and Wortis 2002).  
The functions of B1 cells are threefold. First, they are producers of natural Ig which 
are typically polyreactive IgM with modest affinity towards phosphorylcholine found on gram 
positive microbes such as streptococcus pneumoniae. These Ig were formed without antigen 
exposure through infection or immunisation. As much as 90% of serum IgM during health is 
produced by B1 cells (Sidman, et al. 1986). Not only do natural Ig recognise potential 
microbial threats, they can also promptly sense apoptosing cells which may be necessary to 
prevent an overwhelming autoimmunity during normal cell death (Chen, et al. 2009). These 
natural antibodies have been observed to suppress TNF-ɑ and IL-6 by macrophages during 
LPS stimulation (Chen, et al. 2009). Finally, more recent literature suggests that within the B1 
cell family, there is a group of GMCSF-producing cells found predominantly in the spleen that 
are crucial for protection against intraabdominal and respiratory microbial infections (Rauch, 
et al. 2012).  
The presence of B1 cells in humans has also been confirmed using a “reverse 
engineering strategy”. Rather than identifying human B1 cells using cell surface markers 




cells which produce large amounts of IgM, are efficient at T cell stimulation and have chronic 
intracellular signalling (Rothstein, et al. 2013). Using this criteria, a number of papers have 
identified human CD20+ CD27+ CD43+ B cells as most resembling the murine B1 cell 
population (Griffin, Holodick and Rothstein 2011) (Griffin, Holodick and Rothstein 2011). The 
exact proportion of B cells which can be defined as B1 is debatable as CD27 and CD43 do not 
give discrete cell populations on cytometric analysis, however, estimates range from one to 
nine percent of total B cell populations (Descatoire, et al. 2011) (Verbinnen, et al. 2012). 
There has been suggestion that over time, in humans, total B1 cell numbers decline. 
Currently, their physiological relevance in humans remains uncertain, though it has been 
speculated that natural antibodies against antigens such as phosphorylcholine (PC), low 
density lipoprotein (LDL), tau and amyloid may have beneficial effect in warding off age-
related illness such atherosclerosis and dementia.  
B1 cells in humans have also been described to have regulatory capacity through 
production of IL-10. For example, Griffin et al describe a CD11b+ population of B1 cells which 
spontaneously produce IL-10 and suppress TNFɑ production in activated CD4 T cells (Griffin 
and Rothstein 2012).  
 
1.10 BCR signalling 
The BCR has two primary functions: it recognises cognate antigen and commences a cascade 
of intracellular signalling; it is also able to internalise antigen which can subsequently be 
presented to a helper T cell. The surface Ig has no intrinsic signalling capacity but associates 
with a number of other proteins. The Igα and Igβ (CD79a and CD79b) form heterodimer to 
mediate signal transduction to activate a range of the proteins including Lyn, Blk Fyn, Syk and 
Btk kinases. During BCR signalling, a number of concomitant factors determine the cellular 
fates including survival, anergy, apoptosis, proliferation or progression to a plasma cell. These 
factors include the strength and duration of the BCR signal itself as well as signals from other 
receptors such as CD40, IL-21 receptor and BAFF-receptor. In addition, inhibitory proteins 
such as FcγRIIb, CD22 and SIGLEC-10 limit the strength of BCR signalling via recruitment of 





1.11 Antibody and antibody-independent functions of B cells 
The B cell’s primary function was traditionally thought to be antibody production. However, 
the B cell mediates a number of other functions including antigen presentation to CD4 T cells 
and the initiation of cellular immunity. B cells can also orchestrate lymphoid tissue formation 
by secreting molecules such as lymphotoxin (LT). Finally, B cells produce cytokines necessary 




 Figure 1.16. Schematic diagram of the multiple functions of B cells in addition 
to its primary function as an antibody producer. Figure modified from (LeBien 
and Tedder 2008).  
 
1.11.1 Antibody production 
Most abs are secreted into the circulation by terminally differentiated B2 cells termed plasma 


























to proteins, carbohydrates and other biological macromolecules primarily found on bacteria 
and viruses. Abs recognise molecular shapes, or epitopes, via their variable region potentially 
neutralising the pathogens or toxins. Abs may also initiate an effector response by activating 
the complement cascade and ligating Fc receptors found on the surface of immune cells 
(Joller, Weber and Oxenius 2011) (Krause, Dimmock and Morens 1997).  
In terms of diversity, it is possible to generate in the order of 1016 different antibodies 
specific to as many antigens. However, this antibody repertoire practically is limited to at 
most 109 antigens, presumably as it would be physically infeasible to carry any more plasma 
cell clones.  Antibodies directed at self-antigens, or autoantibodies, have been identified as a 
culprit in a number of autoimmune diseases, for example, in systemic lupus erythematosus 
where autoantibodies can inappropriately target a range of tissue antigens.  
The precise factors that support the survival of plasma cells remain controversial. 
Antigen exposure however, at its simplest level, does not seem to induce survival (Manz, et al. 
1998), consistent with the fact that plasma cells do not express a surface antigen receptor 
(BCR), unlike their B cell precursors. Previously, a number of cytokines and chemokines have 
been described to provide a plasma cell survival ‘niche’, that can be produced by a variety of 
cells (Moser, et al. 2006): These include A proliferation-inducing ligand (APRIL) (Belnoue, et al. 
2007), IL-6 (Mohr, et al. 2009) requiring the presence of nearby stromal cells, eosinophils, 
macrophages and neutrophils (Chu, et al. 2014). 
We currently have some, but probably incomplete knowledge of the factors which 
support the survival of plasma cells. Antigen exposure however at its most simple level does 
not seem to induce survival (Manz, et al. 1998). Previously a number of factors have been 
described to promote a survival ‘niche’ (Moser, et al. 2006). These include A proliferation-
inducing ligand (APRIL) (Belnoue, et al. 2007), IL-6 (Mohr, et al. 2009) and the presence of 
nearby eosinophils (Chu, et al. 2014). 
 
1.11.2 Antigen presentation to CD4 T cells 
For a CD4 T cell to generate an adaptive immune response, it must be activated by antigen 
presented in the context of an MHC class II molecule along with co-stimulatory signals. B cells 




by receptor-mediated endocytosis when the cell membrane inwardly buds to create a vesicle 
containing both the receptor and the antigen. The antigen is partially degraded within the 
acidic vesicle and other vesicles containing major histocompatibility complex (MHC) class II 
fuse to antigen-containing vesicles. The vesicle then travels to the cell surface where the 
antigen can be presented to a helper CD4 T cell. B cells are particularly effective APCs due to 
their high affinity antigen receptor, the BCR, and their ability to clonally proliferate. 
Unsurprisingly then, B cell depletion therapies have been effective in diseases which were 
thought to be largely mediated by T cell such as rheumatoid arthritis, multiple sclerosis, and 
type 1 diabetes mellitus (Claes, et al. 2015) (Edwards and Cambridge 2006) (Hinman, Smith 
and Cambier 2014). 
 
1.11.3 Generation and maintenance of secondary lymphoid tissue  
B cells produce LT which shape the architecture of lymph nodes and spleen (Golovkina, et al. 
1999) (Gonzalez , et al. 1998) (Ngo, Cornall and Cyster 2001). The B cells’ ongoing production 
of LTα1β2 is also required for the maintenance of subcapsular sinus macrophages that form a 
protective screen at the perimeter of lymph nodes (Moseman et al., 2012). B cell production 
of vascular endothelial growth factor A (VEGF-A) may also promote intranodal 
lymphangiogenesis and increase antigen and DC distribution within the lymph nodes (Angeli 
et al., 2006). B cells may also be involved in the generation of tertiary lymphoid structures 
that emerge in inflamed organs affected by autoimmunity, for example in Sjogren’s disease, 
rheumatoid arthritis, or type 1 diabetes mellitus (Drayton , et al. 2006) (Luther, et al. 2000). 
These tertiary lymphoid structures appear to be a source of autoantibodies (Cassese, et al. 
2001) (Espeli, et al. 2011). 
 
1.11.4 Production of pro-inflammatory cytokines 
B cells have the capacity to produce cytokines following stimulation, and can impact a variety 
of immune cells (Shen and Fillatreau 2015). IL-6 is a cytokine required for T cell dependent 
antibody responses (Kopf, et al. 1994). B cells can produce this cytokine (Barr, Brown, et al. 
2010) which may contribute to autoimmune pathology, for example, via T-helper 17 (Th17) 




Indeed, B cells from patients with multiple sclerosis also demonstrate increased IL-6 
production compared with healthy controls (Barr, Shen, et al. 2012). B cell production of 
tumour necrosis factor α (TNF-α) and interferon γ (IFN-γ) can also promote Th1 T cells 
(Menard, et al. 2007) and promote macrophage activation (Bao and Cao 2014).  
More recently, innate response activator (IRA) B cells have been described. These 
splenic IgM-positive B cells can produce GM-CSF in response to lipopolysaccharide (LPS) and 
in turn mobilise neutrophils (Rauch, et al. 2012). The cell type contributes significantly to 
pathogen containment in mouse models of sepsis (Weber, et al. 2014) but may exacerbate 
atherosclerosis via Th1 cell activation (Hilgendorf , et al. 2014). These B cells are thought to 
originate from B1 B cells, a subset found in higher numbers in peritoneal and pleural cavities 
(Griffin, Holodick, & Rothstein, 2011; Martin & Kearney, 2001).  
 
1.12 Acute kidney injury (AKI) and immune cells 
In the context of clinical renal medicine, AKI remains a common condition which can have 
serious long-term consequences. Modulating the immune response has emerged as a 
potential strategy for the treatment of AKI over the past decade, however there has been 
relatively little research into the role of B cells in AKI. In this section, I summarise a number of 
disparate strands of research which are the basis of the experiments described in Chapter 2.  
 
1.12.1 AKI definition, classification and prognostication 
AKI, previously called acute renal failure, is the sudden decline in kidney function that 
disturbs metabolic, electrolyte and fluid volume balance (Oleska and Bagshaw 2014). The 
causes of AKI are varied and often multifactorial, however, intravascular volume depletion, 
sepsis and nephrotoxic drugs are the most common causes.  
There are at least 30 different published sets of clinical criteria defining AKI, however, 
the RIFLE criteria (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease), 
AKIN criteria (Acute Kidney Injury Network) and more recently the KDIGO criteria (Kidney 
Disease: Improving Global Outcomes), which amalgamates the RIFLE and AKIN, are now used 




while recognising that serum creatinine represents a late biomarker lagging many hours 
behind initial renal insult.  
 
Stage Serum creatinine Urine 
output 
1 1.5–1.9 x baseline 
OR 
≥0.3 mg/dl (≥26.5 umol/l) increase 
<0.5 ml/kg/h 
for 6–12 hours 
2 2.0–2.9 times baseline 
 
<0.5 ml/kg/h 
for ≥12 hours 
3 3.0 times baseline 
OR 
Increase in serum creatinine to ≥4.0 mg/dl (≥353.6 
mmol/l) 
OR 
Initiation of renal replacement therapy 
OR 
In patients <18 years, decrease in eGFR to o35 ml/min 
per 1.73 m2 
<0.3 ml/kg/h 
for ≥24 hours 
OR 
Anuria for ≥12 
hours 
 
Table 1.3. KDIGO AKI criteria (KDIGO 2012) 
 
Largely incontrovertible, however, is that severity of AKI is directly associated to mortality 
though this link is not necessarily causal (Chertow, Burdick, et al. 2005). 
Progression of AKI to chronic kidney disease (CKD) was first described in the 1960s 
and there is now a wealth of data to show a strong association (Briggs, et al. 1967) (Chawla, 
et al. 2014) (Leung, Tonelli and James 2012) (Venkatachalam, et al. 2010) (Lo, Go and 
Chertow 2009) (Bucaloiu, et al. 2012) (Varrier, Forni and Ostermann 2015). The question that 
has never been fully answered, however, is whether a treatment for AKI can confer long-term 
protection from CKD. One obvious reason for the lack of such a study is that there has never 





1.12.2 AKI epidemiology and cost 
The incidence of AKI is common among hospital in-patients. The largest known meta-study 
compiling data from 312 studies involving approximately 49 million patients predominantly 
from high-income countries estimated mean incidence of AKI among hospital in-patients to 
be 21.6% in adults and 33.7% in children (Susantitaphong, et al. 2013). While there is no 
doubt that a sizeable portion of hospital patients suffer AKI, whether the incidence has 
changed over time remains very difficult to ascertain. Monitoring of patients in hospital has 
become more intensive, therefore more likely to detect AKI. At the same time, modern 
treatments, such as transplantation or coronary angioplasty may themselves cause increased 
incidence of AKI.  
In the US where cost of medical care is often arbitrarily exorbitant, one recent study 
places the increase in cost of having AKI as $7933 per patient (Silver, Long, et al. 2017). In the 
UK, in one often-quoted paper, it has been estimated that the annual hospital-related cost to 
the National Health Service of AKI is approximately one billion pounds or slightly more than 
1% of the overall annual NHS budget (Kerr, et al. 2014). While these costs vary considerably 
between studies (Table 1.4), what is clear is that AKI and in particular dialysis adds on 
considerable cost to hospital care.   
Study Country Cost 
(Hamel, et al. 1997) United States Median in-hospital cost:  
With dialysis US $31,991 
(Chertow, Burdick, et al., Acute 
kidney injury, mortality, length 
of stay, and costs in hospitalized 
patients 2005) 
United States Mean increase in cost: 
KDIGO 1: US $5,510 
KDIGO 2: US $8,999 
(Manns, et al. 2003) Canada Mean in-hospital cost: 
No dialysis: US $47,694 
With dialysis: US $56,035 
(Fischer, et al. 2005) US Median in-hospital cost: 
All AKI: US $2,600 
With dialysis: $4,300 





Table 1.4 Previously published papers on the financial cost of AKI (modified 
from (Silver and Chertow 2017)).  
 
1.12.3 Immune cells and AKI  
One approach to treat AKI has been to modulate the immune response seen in AKI. Virtually 
all types of immune cells have been implicated in the condition, often simplistically with pro- 
and others with anti-inflammatory and repairing effects (Linfert, Chowdhry and Rabb 2009) 
(Bonavia and Singbartl 2017) (Jang and Rabb 2015) (Lee, et al. 2017).  
 
1.12.4 Neutrophils 
Neutrophils are trafficked to the kidneys during AKI and the mechanism by which these cells 
marginate to the vascular endothelium and eventually enter the renal interstitium during 
sterile inflammation has been investigated in a number of studies (Awad, et al. 2009) 
(Bolisetty and Agarwal 2009). What actually causes neutrophils to mobilise in the first place 
RIFLE R US $11,234 
RIFLE I US $20,461 
RIFLE F US $34,155 
(Laukkanen, et al. 2013) Finland Mean in-hospital cost: 
With dialysis: US $28,527 
(Hobson, et al. 2015) US Mean increase in cost: 
RIFLE R US $10,700 
RIFLE I US $15,200 
RIFLE F US $38,200 
(Zeng, et al. 2014) US Mean increase in cost: 
KDIGO 1 US $5,400 
KDIGO 2 US $15,200 
KDIGO 3 US $27,300 
(Kerr, et al. 2014) UK Total cost to UK National Health Service: 
UK £1,020,000,000 per annum 
(Silver, Long, et al. 2017) US Mean increase in cost: 
All AKI: $1,795 




from neutrophil reservoirs remains unclear (Sokol and Luster 2015). In general, though there 
have been some exceptions, the inhibition of neutrophil endothelial adhesion and activation 
or the depletion of neutrophils have led to lessening of the severity of AKI in animal models.  
One of the earliest studies of immune responses in AKI showed that in rabbits and 
rats, there was no difference in outcome following administration of monoclonal antibody 
clone 60.3 against CD18 which prevents neutrophil adhesion to the endothelium or an anti-
neutrophil serum to reduce neutrophil numbers to negligible levels (Thornton, et al. 1989). 
Subsequent murine studies however show a roughly halving of serum urea and creatinine 
with anti-neutrophil serum treatment following renal pedicle clamping (Kelly, et al. 1996). It is 
not completely clear how these contradictory findings can be reconciled. One obvious 
difference is species differences. Looking closely at the data, perhaps another reason for this 
was the very severe AKI induced in Thornton’s surgical clamping model. Though it is difficult 
to compare leporine biochemical parameters to those from other species, typical serum urea 
levels at a 48 hour timepoint were 63±16 mg/dl and 153± 9 mg/dl for 38 and 50 minutes of 
renal pedicle clamping. While these clamping times are roughly consistent with other 
published methods, the high urea levels suggest disease severity may have surpassed a 
theoretical ‘point of no return’ beyond which amelioration of renal function may simply not 
be possible due to the overwhelming amount of tissue damage from cell death.  
Inhibiting activation of neutrophils is another strategy for reducing their inflammatory 
effects. By the use of alpha-melanocyte-stimulating hormone which inhibits neutrophil 
activation by an unknown mechanism, Chiao and colleagues showed it was possible to 
ameliorate AKI (Chiao, et al. 1997).  
Cell adhesion may be inhibited on the neutrophil aspect or the endothelial aspect.  On 
neutrophils CD11a and CD11b are abundantly found. The molecules form adhesion 
complexes with CD18 and inhibition of these membrane proteins, using clone TA-3 against 
CD11a and OX-42 against CD11b, can result in reduced neutrophil infiltration and 
amelioration of AKI (Rabb, Mendiola, et al. 1994 ) (Rouschop, et al. 2005) 
On the other hand by manipulating the adhesion of neutrophils into organ tissue 
using both a global ICAM-1 knockout model and a neutralising anti-ICAM-1 antibody, Kelly 




histological outcomes (Kelly, et al. 1996). While neutrophils avidly engage with ICAM-1, as we 
will see later, it is possible that other cell types, namely B cells, may also employ a similar 
tactic for entry into renal tissue.  
More recently, inhibition of vascular adhesion protein 1 with the monoclonal antibody 
RTU-1096 which is predominantly expressed by pericytes during AKI prevented the 
infiltration of neutrophils but not macrophage or T cell populations into renal tissues (Tanaka, 
et al. 2017). It appears that inhibiting the entry of neutrophils ameliorated AKI. Inhibition of 
another neutrophil chemoattractant pathway, the leukotriene B4 receptor axis either 
through knockout models or by chemical inhibitors, SC-57461A and U-75302, had similar 
effects on AKI outcomes (Deng , et al. 2017). Taken together, inhibition of neutrophil 
infiltration into renal tissue appears to be an effective strategy in ameliorating AKI.  
Interestingly, to my knowledge, there have been no works which have looked at the 
effects of directly depleting neutrophils on AKI using a GR1 antibody in a murine model – 
perhaps one of the most obvious ways of depleting neutrophils – or using low dose anti-GR1 
antibody to inhibit neutrophil egress into renal tissue (Wang, et al. 2012). More 
sophisiticated experiments to determine the immune mechanism by which neutrophils exert 
a largely negative effect during AKI have not been undertaken to date.  
Moreover, the precise relationship of cellular changes observed in murine 
experiments to human pathophysiology of AKI is difficult to assess. However, 
histopathological assessment of kidney sections with acute tubular necrosis from, for 
example, hypoperfusion, show increased numbers of neutrophils within renal tissue 
consistent with the observations in murine models of AKI.  Clinical trials specifically targeting 
neutrophils in AKI have yet to be undertaken and will be required to determine their precise 
role in human AKI. 
 
1.12.5 Macrophages  
Macrophages have come to be defined as having different functions during two phases of AKI. 
On the one hand, in the earlier stages of disease, monocytes enter or macrophages 
proliferate in the kidney to generate an inflammatory milieu, while in the latter stages, 




 Infiltration of macrophages into the kidneys has been observed especially in the outer 
medulla, peaking at about day 5 following renal pedicle clamping in rats (Ysebaert, et al. 
2000). How chemokines cause monocyte trafficking in the context of AKI is not well described, 
but previous studies have shown that the cytokines CCL2-5, CCL8, CCL13-16 and CX3CL1 
induce mobilisation in other models (Chung and Lan 2011). Entry of monocytes into the 
kidneys can be prevented by blockade of the surface protein B7-1 or CD80 (clone: 3H5) (De 
Greef, Ysebaert and Dauwe, et al. 2001). Interestingly, De Greef’s study showed 
improvements in serum creatinine at earlier timepoints of 24 and 48 hours but not at any 
later timepoints following this intervention. Blockade of CX3CL1, which is thought to be 
predominantly produced by epithelial cells during AKI, has been shown to reduce infiltrating 
macrophages, however this has not resulted in improvement of renal parameters. Another 
macrophage chemotractant, osteopontin, has been shown to reduce macrophage infiltration 
but not affect disease course (Persy, et al. 2003). 
 A number of studies have presented data that depletion of macrophages using 
liposome-encapsulated clodronate improved multiple outcome measures after 24 hours in a 
surgical IRI model (Day, et al. 2005) (Jo, et al. 2006). By day 3, however, clodronate-based 
depletion of macrophages has shown no difference in the outcome of cisplatin-induced and 
IRI-induced AKI models (Lu, et al. 2008) (Jo, et al. 2006). Hints that macrophages may affect 
longer term outcomes came when longer fibrosis experiments were done using repeated 
injections of clodronate over a four to eight week period (Ko, et al. 2008). Macrophage 
depletion seems to have attenuated renal interstitial fibrosis.  
In a key paper, which recapitulated the duality of macrophages and the reasons for at 
times contradictory results, Lee and colleagues showed the evolving phenotype of 
macrophages in the kidney over a time course during AKI (Lee, et al. 2011). M1 macrophages, 
which have a generally pro-inflammatory phenotype, predominated the early stages of AKI 
while M2 macrophages with a more anti-inflammatory reparative phenotype appeared 
during the later stages. Depletion, therefore, of macrophages during the onset of AKI 





Thus, the literature suggests that macrophages can play both positive and negative 
roles in AKI pathogenesis and the subsequent development of fibrosis. One possible 
explanation for this is the differential effects of monocyte-derived macrophages which may 
be recruited during acute injury and have a more M1 profile, and tissue-resident 
macrophages which are prenatally seeded and have a more M2-skewed profile.  In vitro, the 
factors that polarise monocytes or bone marrow pre-cursors into and M1 or M2 phenotype 
have been described. For example, IFN-γ, LPS, GM-CSF, oxidative, fatty acid and HMGB1 
polarise macrophages to a more M1 phenotype whereas IL-4, IL-10, IL-13, TGF-β, M-CSF, 
AMP and GC induce more of an M2 phenotype (Zhang, et al. 2017). Differences in these local 
signals could modulate macrophage polarisation during AKI. 
 
1.12.6 Dendritic cells 
Dendritic cells (DCs) during AKI have been shown to be the predominant source of TNF-ɑ 
(Dong, et al. 2007). Ablation of dendritic cells using CD11c-diptheria toxin receptor transgenic 
before or at the time of cisplatin-induced AKI resulted in worsened outcomes (Tadagavadi 
and Reeves 2010). However, recent work in our own laboratory and others’ suggest that 
CD11c is not exclusively expressed on DCs and may be expressed on some macrophages, 
therefore, the ablated population remains unclear. Indeed all of the experimental strategies 
used to deplete kidney mononuclear phagocytes such as clodronate liposomes, CD11b or 
CD11c diphtheria toxin receptor mediated cell depletion are subject to indiscrimate 
depletions of multiple cell lines.  
 
1.12.7 T cells  
The evidence for the role of T cells have been difficult to interpret. Mice which are globally 
deficient in recombinase activating gene (RAG1) and do not have B or T cells are not 
protected from AKI, however, adoptive transfer of T cells into these mice confers protection 
(Park, et al. 2002) (Burne-Taney, Yokota-Ikeda and Rabb 2005). While these data suggest a 
regulatory role for T cells, other studies have suggested that the absence of CD4 and CD8 T 
cells actually confers protection from AKI (Rabb, Daniels , et al. 2000). Athymic mice appear 




2001). Studies which used mice deficient in CD4 T cells but not CD8 T cells were protected 
from AKI (Yokota, et al. 2003). En masse absence of multiple T cell phenotypes may be 
contributing to these contradictory results as well as the use of congenitally T cell deficient 
mice, which makes it very difficult to interpret, given that other immunological cells may not 
be normal in the absence of T cells.  
Therapeutically, T cell modulating agents such as tacrolimus and mycophenolate 
mofetil as well as the blockade of the T cell CD28-B7costimulatory pathway with CTLA4/Ig-
fusion protein have been effective in attenuating AKI (Sakr, et al. 1992) (Jones and Shoskes 
2000) (Chandraker, et al. 1997) (Takada, et al. 1997).  
 
1.12.8 Experimental models of AKI 
Almost twenty different models of AKI have been used in previously published experiments 
(table 1.5) (Singh, et al. 2012). This large number of approaches reflects an attempt to model 
the variety of aetiologies which can induce AKI. For example, gentamicin, cisplatin, contrast 
media and NSAIDs mimic respective iatrogenic drug-induced AKIs. In contrast surgical 
clamping of the renal pedicle mimics transient renal hypoprofusion from dehydration or 
conditions found during transplantation. Other models reflect AKI from environmental causes 
or infection. Each of these models occupies a different position within a spectrum of clinical 







Bipyridyls ND Low ND ND 
Cisplatin Low High High Low 
Contrast media Low High High High 
Ferric 
nitrilotriacetate 
ND Low ND ND 





Table 1.5. Different methods of inducing AKI in experimental models and the 
author’s assessment of the agent. Original list of models taken from Singh 2012. 
In a number of models, the characteristics of the model remained unclear. For 
example, the renal specificity of ferric nitrilotriacetate was unclear from the 
literature. Where this was the case, I have written “ND”, which stands for not 
determined.  
 
 In our experiments, we sought a model of AKI which i) was technically uncomplicated, 
ii) was frequently used by other researchers, iii) was sterile in its induction of an immune 
Gentamicin ND High High ND 




Iphosphamide ND Low ND ND 
Ischaemia-
reperfusion 
High High Low High 
Mercuric chloride ND Low ND ND 
NSAIDs Low High High Mod 
Osmotic nephrosis ND Low ND ND 
Paracetamol Low High High Low 
Potassium 
dichromate 
ND Low ND ND 
S-(1,2-dichlorovinyl)-
L-cysteine (DCVC) 
ND Low ND ND 
Sepsis Low High Mod Low 




response and iv) had relatively few known off-target effects. Folic acid appeared to fulfil this 
criteria.  
The mechanism of action is not fully understood and multiple pathways may 
contribute to its pathophysiology: Following administration, there is deposition of folic acid 
crystals along with associated apoptosis and necrosis of tubular cells. Reports suggest that 
following its administration in high doses, there is downregulation of B-cell lymphoma-extra 
large (Bcl-xL), an anti-apoptotic protein and an increase in tumor necrosis factor-a (TNF-a) 
(Wan, et al. 2006). Others have shown that the folic acid creates oxidative stress and 
consequently tissue damage: Levels of antioxidant enzymes such as superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were significantly decreased while 
lipid peroxidation (LPO) levels, a widely used manifestation of oxidative stress, increased 
(Gupta, et al. 2012). Mitochondrial dysfunction, as with most forms of experimental and 
clinical AKI, has been shown to occur following folic acid induced AKI (Stallons, Whitaker and 
Schnellmann 2014). Finally, also perhaps not surprisingly, nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) expression is increased in the kidneys during folic acid 
induced AKI and the suppression of this transcription factor has been found to ameliorate 
disease (Kumar, et al. 2015). The extent to which these described pathways are present in all 
forms of AKI and how much is unique to folic acid induced AKI remains unclear. 
On a practical level, folic acid provides an experimentally convenient substance. The 
nephrotoxin, which comes in powder form, is soluble within an alkaline medium such as 
sodium bicarbonate and consistent batches can be produced in 12 hours. Administration is 
via an intraperitoneal injection, which is technically unchallenging. The model has been used 
in a large number of papers. Although the whole list of references have not been included in 
this thesis, in 2018 alone, more than ten publications cited on the biomedical database 
Pubmed used a folic acid-induced model of AKI (Zhou, et al. 2018) (Honarpisheh, et al. 2018) 
(González-Guerrero, et al. 2018). 
Although folic acid nephropathy is not directly clinically relevant (given that toxic 
doses in humans would require in excess of a thousand standard 5mg tablets) we felt that the 
drug’s direct eventual effect on inducing necrosis in the tubules provided an ideal 




whereas other more clinically relevant models have a multitude of off target effects. For 
example, while paracetamol-induced AKI is common, the model involves considerable liver 
injury or in the case of cisplatin, which is again a common cause of AKI, there are 
considerable effects on immune cells. 
 
1.13 B cells and AKI 
Relatively little is known about the role of B cells in AKI and what is published is often 
conflicting suggesting multiple roles which can both ameliorate and exacerbate disease. 
Initial studies showed that uMt mice which are deficient in mature B cells had less severe 
disease following short-term renal pedicle clamping (Burne-Taney, Ascon, et al. 2003). 
Following on from this work, Rabb and colleagues showed CD126 positive plasma cells 
trafficking into the kidney post-AKI to have a detrimental role in AKI (Jang, Gandolfo, et al. 
2010). Treatment with anti-CD126 antibody have been shown to increase tubular 
proliferation and reduce tubular atrophy.  
In contrast, IgM anti-leucocyte autoantibodies produced by B1 cells may have a 
protective effect in AKI (Lobo, et al. 2012). Other groups have shown that uMT mice fare 
worse following AKI (Renner, et al. 2010). It is not clear why there have been such 
contradictory results from these projects given the similar methodology of inducing AKI with 
renal pedicle clamping and similar timepoints. One possibility, as shown in later data, is that 
mice are highly variable in their susceptibility to AKI. Age-matching may be inadequate to 
generate comparable control groups with weight matching being potentially more useful.  
Interestingly, the effect of AKI on B cell antibody production has also been 
investigated (Fuquay, et al. 2013). Mice immunised with foreign antigen 24 to 96 hours 
following AKI had increased levels of antigen specific IgG1. Such findings have implications for 
kidney transplantation where the donor kidney (and sometimes the recipient’s native 
kidneys) inevitably experience ischaemia perfusion injury and AKI would potentially augment 





1.13.1 B cells and CD11b 
CD11b, also known as integrin alpha M (ITGAM), forms a heterodimeric integrin complex with 
CD18 called alpha-M beta-2 (αMβ2). This complex is also called macrophage antigen-1 (MAC-
1) or complex-receptor (CR3) and is heavily expressed monocytes, granulocytes, 
macrophages and NK cells. Perhaps best known of MAC-1’s many ligands is intercellular 
adhesion molecule 1 (ICAM1) which can attach to an activated form of CD11b and can be 
found on endothelium of inflamed tissue (figure 1.17). In addition, other ligands of MAC-1 
include LPS (Wright and Jong 1986), beta amyloid (Zhang, et al. 2011), the damage-associated 
molecular pattern (DAMP) high mobility group box one (HMGB1) (Gao, et al. 2011), viruses 
(Morrison, Simmons and Heise 2008), nucleotides such as oligodeoxynucleotide 
(Benimetskaya, et al. 1997) and double-stranded RNA (Zhou, et al. 2013).  
 
 
Figure 1.17. Schematic drawing of the MAC-1 consisting of CD11b and CD18 on 
the surface of the leucocyte (eg. myeloid cell or B cell) and its interacting 
protein, ICAM-1 complex on the surface of the endothelial cell.  
 
 Signalling via MAC-1 has been reported to induce expression of IL1β (Fan and 
Edgington 1993) (Rezzonico, et al. 2000), TNFɑ (Perez and Roman 1995) and tissue factor 
(Fan and Edgington 1998).  
Relatively little work has been done on B cell expression of CD11b. Moreover, the 
protein’s function when expressed on B cells remains unclear. CD11b expression has been 
previously noted on peritoneal B1 cells and may reflect a later developmental stage (Ghosn, 




early descriptions. Others have noted, somewhat controversially, that CD11b positive B1 cells 
in humans may have a role in expanding and stimulating T cells in lupus (Griffin and Rothstein 
2011) (Griffin, Quach, et al. 2012) (Reynaud and Weill 2012). In one of the few papers known 
to discuss the function of CD11b on B cells, Kawai et al using in vitro experiments observed 
that CD11b may have an effect on its migratory potential (Kawai, et al. 2005).  
 
1.13.2 Siglec-10 and Siglec-g 
Siglecs (Sialic acid-binding immunoglobulin-type lectins) are a family of 
transmembrane proteins found on a wide range of immune cells which bind to sialic acids, a 
type of nine-carbon sugar, and mediate many different biological interactions (Chen, Brown 
and Zheng 2014). Siglec-g is expressed on B cells and to a lesser extent on dendritic cells and 
macrophages and are thought to be an inhibitor of B1a activation. The human orthologue of 
Siglec-g is Siglec-10. This section briefly discusses how Siglec-g regulates BCR signalling, binds 
to its ligands and plays a role in regulating immune responses. 
 There are two different SIGLECs found on the B cell surface: SIGLEC 2 (also known as 
CD22) and Siglec-g. Within the cytoplasmic domain of Siglec-g, there is an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) domain as well as an ITIM-like domain which are able 
to activate Src homology region 2 domain-containing phosphatase-1 (SHP-1) and inhibit B cell 
receptor signalling (Pfrengle, et al. 2013) (Whitney, et al. 2001). The absence of Siglec-g leads 
to increased calcium influx in B cells upon BCR activation (Hoffmann, et al. 2007). Although 
Siglec-g is expressed on both B2 and B1 cells, absence of the protein leads to increased BCR 
signalling in B1 cells (Hoffmann, et al. 2007) (Ding, et al. 2007).  
  Siglec-g can bind to both ɑ2,6- and ɑ2,3- linked sialic acids (Duong, et al. 2009). These 
sialic acids can be presented to the Siglec-g either in a cis fashion from surface of the same 
cell or in a trans fashion from the surface of another cell. It is unclear what the effect of non-
attached sialic acids are on Siglec-g. To investigate the role of Siglec-g ligands Hutzler et al 
produced a knock-in mouse in which the ligand binding portion of the Siglec-g protein was 
altered so that both ɑ2,6- and ɑ2,3- linked sialic acids were unable to bind (Hutzler, et al. 
2014). In doing so, they noted that this knock-in mouse called Siglec-g-R120E was 




augmented population of B1a cells. This series of experiments suggested the chronic 
requirement of a Siglec-g agonist for its function. It has been suggested that one possible 
reason for why Siglec-g functions on B1 cells, and not B2 cells, is presence of higher 
concentrations of ɑ2,3- linked sialic acids on B1 cells which may be providing basal 
stimulation of the protein and consequent BCR inhibition.  
 Phenotypical differences have been noted in Siglec-g deficient mice compared to their 
wild type counterparts. For example, the B1 (both B1a and B1b) population is greatly 
expanded in these mice (Hoffmann, et al. 2007). In addition, autoimmunity can 
spontaneously can occur in the Siglec-g knockout mice on a C57BL/6 background (Müller, et 
al. 2015). Siglec-g knockout mice have a propensity towards worse collagen-induced arthritis 
following immunisation or lupus-like disease when Siglec-g knockouts were crossed with a 
lupus-prone MRL/lpr mouse (Bökers, Urbat, et al., 7 2014). When mice are deficient in both 
Siglec-g and SIGLEC-2, it has been observed that they develop spontaneous lupus-like disease 
with age (Jellusova, et al. 2010).  
 
 
Figure 1.18. Diagram of the signalling pathway of Siglec-g/10 showing its 
inhibition of BCR signalling via activation of SHP-1. 
 
Siglec-g is expressed predominantly by B cells and to a limited extent by dendritic cells 
(figure 1.19).  Given that the Siglec-g knockout has an expanded B1a cells population and 
reduced threshold of activation of the B cell population, it has been used as a model to 
investigation excessive B cell – especially B1a cell – activity in a model of acute kidney injury 




regulate B cell activity such as paired immunoglobulin-like receptor B (PirB), B- and T-
lymphocyte attenuator (BTLA, CD72), FcγRIIb (CD32), programmed cell death protein 1 (PD-1, 
CD279) and platelet endothelial cell adhesion molecule (CD31) (Pritchard and Smith 2003) 
(Odorizzi and Wherry 2012). However, the expression of these other inhibitory proteins was 
not limited to B cells but was present in a range of other immunological cell types (figure 
1.20): For example, BTLA is also expressed on T cells. Consequently, it was felt that Siglec-g 




Figure 1.19 (above). Gene expression of Siglec-g in different leucocyte subsets. 
Data from the Immunological Genome Project Gene Skyline application 
(Immunological Genome Project 2019).  
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Figure 1.20 (above). Gene expression of PirB, BTLA, PD-1, CD31 and FcγRIIb in 
different immunological cell types. Data from the Immunological Genome 
Project Gene Skyline application (Immunological Genome Project 2019). 
 
1.14: In vivo manipulation of regulatory B cells 
There is now a wealth of research suggesting that B-regs play an important role in a range of 
conditions, therefore B-reg-based immunotherapy may be a potentially fruitful avenue for 
novel treatments. Virtually all in vivo studies have either been observational studies in 
humans or transfer experiments in mice. In clinical practice, however, cell-based therapies 
can be costly and are therefore less likely to be feasible for broad clinical application. Thus, 
the crucial question is whether B-regs can be induced in vivo pharmocologically. In this 
section, I will discuss a number of disparate fields and consider recent research into B-regs 




 As early as the late 1960s, there was evidence that a group of splenocytes from 
recently immunised mice, when transferred into another mouse, could suppress the 
production of antibodies (Morris and Möller 1968). However, there was no convincing 
evidence at the time that this was mediated by B cells. In the 1970s, a number of groups 
showed that splenocytes which were depleted of B cells failed to suppress delayed 
hypersensitivity reactions in passive transfer experiments (Katz, Parker and Turk 1974) (Neta 
and Salvin 1974) (Rosser & Mauri, 2015). Subsequently, Wolf and colleagues showed that 
mice deficient in mature B cells were unable to recover from experimental autoimmune 
encephalitis, a murine experimental model of human multiple sclerosis (Wolf, et al. 1996).  
The mediator of immune regulation produced by B cells that has received most 
attention is IL-10, although other proteins such as IL-35, TGF-β, granzyme-B and PDL1 have 
been implicated. IL-10 produced by B cells has been shown to suppress inflammation in 
colitis, EAE and collagen-induced arthritis (Mizoguchi, et al. 2002) (Fillatreau, et al. 2002) 
(Mauri, Gray, et al. 2003). TGF-β from LPS-stimulated B cells has been shown to induce 
anergy and apoptosis in T cells. More recently, IL-35 from B cells has also been shown to be 
crucial in controlling EAE and experimental uveitis (Shen, Roch, et al. 2014) (Wang, et al. 
2014). Contact-dependent mechanisms such as PDL1 expression (Khan, et al. 2015)and direct 
granzyme-B-dependent cytotoxicity have also been noted as immunomodulatory 
mechanisms employed by B cells (Chesneau, et al. 2015).   
In mice, several groups have identified IL-10-producing B cells within a number of B 
cell subsets including B1, transitional and marginal zone subsets (Miles, Simpson, et al. 2018) 
(Evans, et al. 2007) (Gray, Miles, et al. 2007). As in mice, human IL-10-producing B cells are 
present within different subsets, including transitional and memory CD27 positive B cells. 
Several markers, such as CD5, CD1d, Tim-1, CD9 and CD80, have also been reported to be 
coexpressed by regulatory cells (Blair, Noreña, et al. 2010) (Ding, et al. 2011) (Iwata, et al. 
2011) (J. Sun, et al. 2015) (van de Veen, et al. 2013).  
The available data would suggest that there is not a separate population of regulatory 
B cells. When we refer to dedicated populations, this is frequently defined by the presence of 
one or more transcription factors that determine cell phenotype and allow the identification 




the case of regulatory B cells, specific transcription factors or markers identifying a distinct 
population of regulators has not been described. The current evidence suggests that a 
regulatory B cell simply produces relatively more anti-inflammatory cytokines than 
inflammatory ones, and that this is determined by environmental cues, as explained later for 
example, by cytokines such as IL-2. 
 
1.14.1 Diseases implicated by regulatory B cells: Multiple sclerosis / EAE 
One of the earliest experiments observing the role of B cells in negatively regulating 
autoimmunity was in experimental autoimmune encephalomyelitis (EAE), a murine disease 
model thought to mimic multiple sclerosis seen in humans. Mice lacking the µ chain 
transmembrane region (µMt), therefore unable to generate mature B cells, failed to recover 
from EAE, suggesting that B cells may play a non-redundant role in limiting inflammation 
(Wolf, Dittel, Hardardottir, & Janeway, 1996). Subsequently, experiments using chimeric mice 
with B cell specific IL-10 deletion failed to suppress a type I immune response (Fillatreau, et al. 
2002). 
 
1.14.2 Arthritis / Collagen-induced arthritis 
Mauri and colleagues have shown in a series of experiments that B-regs play a central role in 
controlling collagen-induced arthritis (CIA), a murine model of rheumatoid arthritis (Carter, 
Rosser and Mauri 2012) (Evans, et al. 2007) (Mauri, Gray, et al. 2003). This suppression is 
mediated via IL-10 which inhibits T helper 1 differentiation. Later studies suggested that 
there was an enrichment of B-regs in a CD21hi, CD23hi, IgMhi population which was labelled 
transitional 2-marginal zone precursor population. It is likely that this population is plastic, 
given that these cells, as the name suggests, are precursors of marginal zone B cells. 
 
1.14.3 Colitis 
A CD1d positive population of B-regs have been shown to be crucial immune regulators in the 
mesenteric lymphoid tissue during gastrointestinal inflammation via IL-10 which had effects 





1.14.4 Systemic lupus erythematosus 
In healthy subjects, CD24hi CD38hi B cells suppress differentiation of T helper 1 cells but this is 
impaired in patients with SLE (Blair, Noreña, et al. 2010). More recently, it has emerged that 
normal crosstalk between plasmacytoid dendritic cells and CD24hi CD38hi B cells induced an 
appropriate balance of IL-10 and TNF-α production. This balance appears to be perturbed in 
patients with SLE (Menon, et al. 2016). 
 
1.14.5 Tolerance to apoptotic cells 
It may not be necessary to implicate the role of regulatory B cells to particular clinical 
conditions, but rather to the underlying mechanism at play. Specifically, immune tolerance to 
apoptotic cells – the breakdown of which is thought to induce a range of autoimmune 
conditions – may be mediated by regulatory B cells. For example, Gray et al showed that B 
cells co-cultured with apoptotic cells take on an immunomodulatory phenotype by provision 
of IL-10 (Gray, Miles, et al. 2007). Subsequent work has shown exposure to apoptotic cells 
results in the engagement of TLR9 pathways (Miles, Heaney, et al. 2012) and that B1a cells, 
which are identified by the CD43+CD19hiCD5+IgMhiIgDlo signature, are responsible for the 
majority of the IL-10 produced (Miles, Simpson, et al. 2018).  
 
1.14.6 Transplantation  
Tolerance towards a transplanted organ graft with minimal immunosuppression remains the 
gold standard of modern transplantation. It has become apparent from a number of studies 
that lower rates of antibody-mediated rejection are associated with enrichment of a CD24hi 
CD38hi population (Shabir et al., 2015). In addition, the balance between the production of IL-
10 and pro-inflammatory cytokines such as IL-6 and TNF-α may be important in regulating 
immune responses. For example, a reduction in the numbers of CD24hi CD38hi B cells, which 
produce the highest ratios of IL-10 to TNF-α, is associated with worse allograft outcome in 
renal transplant recipients (Cherukuri et al., 2014). In contrast, in ‘operationally tolerant’ 
patients with drug-free long-term graft function due simply to non-compliance, a significant 




CD20- CD38+ CD138+ plasma cells have been observed (Chesneau et al., 2015; Chesneau et al., 
2014; Nova-Lamperti et al., 2016).  
 














 Spleen IL-10 (Blair, Chavez-
Rueda, et al. 
2009) 
(Carter, Rosser 
and Mauri 2012) 
(Evans, et al. 
2007) 
(Schioppa, et al. 
2011) 
Marginal zone CD19, CD21, 
CD23- 
 Spleen IL-10 (Bankoti, et al. 
2012) 
(Gray, Miles, et 
al. 2007) 
(Miles, Heaney, 
et al. 2012) 
B1a CD43, CD19, 
CD5, IgM, IgDlo 
 Spleen, 
peritoneum  
IL-10 (Miles, Simpson, 
et al. 2018) 
B10 CD5, CD1d CD24, CD27 Spleen, blood IL-10 (Horikawa, et al. 
2013) 
(Iwata, et al. 
2011) 
(Matsushita, 
Horikawa, et al. 
2010) 
(Yanaba, et al. 
2008) 
Plasma cells B220, CD138, 
MHC-11lo 
 Spleen IL-10, IL-35 (Neves, et al. 
2010) 
(Shen, Roch, et 
al. 2014) 
TIM-1 CD19, TIM-1  Spleen IL-10 (Wilson 2017) 
(Ding, et al. 
2011) 
(Xiao, et al. 
2012) 










Immature cells  CD19, CD24, 
CD38 
Blood IL-10 (Blair, Noreña, 
et al. 2010) 
(Bosma, et al. 
2012) 




B regulatory 1  CD19, CD25, 
CD71 
Blood IL-10 (van de Veen, et 
al. 2013) 
PDL1hi 
Found in multiple 
splenic 
compartments. 
CD19, PDL1  Spleen PDL1 Khan 2015 
 




Systemic lupus erythematosus  Blair et al, 2009. 
Blair et al, 2010. 
Colitis  / Inflammatory bowel 
disease 
Mizoguchi et al, 2002 
Arthritis Mauri et al 2003. 
Evans et al 2007. 
Carter 2012.  
Hypersensitivity reactions Katz, 1974.  
Neta 1974. 
Van de veen 2013. 
Multiple sclerosis / Experimental 
autimmune encephalitis 
Wolf et al, 1996.  
Mann et al, 2007. 
Filatreau et al 2002. 
Matsushita et al, 2010.  
Transplantation Nova-Lamperti et al, 2016.  
Cherukuri et al, 2014.  
 
Table 1.7 (above) Disease processes and conditions in which B-regs are implicated.  
 
1.15 Previous studies in IL-2 therapy and regulatory T cells 
The effect of recombinant human IL-2 therapy on T-cells illustrates the bimodal effects of the 




to induce survival, proliferation and most importantly differentiation of naive T cells into 
effector T cells (Robb 1984). For this reason, IL-2 was approved by the United States Food 
and Drug Administration as perhaps one of the earliest oncological ‘immunotherapies’ for 
renal cell carcinoma in 1992 and melanoma in 1998, but was not widely prescribed due to its 
large side-effect profile which included vascular leak syndrome and renal and liver 
impairment (Rosenberg 2014).  
Paradoxically, in the 1990s genetically altered mice deficient in various components of 
the IL-2-IL-2-receptor axis developed autoimmunity, rather than immunodeficiency, which 
one might assume would be the result given the scientific and clinical experience described 
above. IL-2 deficient mice have a high infant mortality rate of about 50% and all of the 
survivors, without exception, develop inflammatory bowel disease (Sadlack, et al. 1993). 
Similarly deficiency of either the ɑ- or β-chain of the trimeric IL-2 receptor (CD25 and CD122 
respectively) led to uncontrolled autoimmunity (Suzuki, et al. 1995) (Willerford, et al. 1995). 
These data helped form the conclusion that IL-2 was necessary for sustaining the regulatory T 
cells in vivo (Yu, et al. 2009). It should be noted that these experiments did not use models of 
T cell specific deletion. The extent to which other cell types are receptive to IL-2 has never 
been fully addressed.  
On the basis of these results, low-dose IL-2 therapy has been applied in humans trials 
where it was thought the therapy would lead to T-reg proliferation, in preference to effector 
T cells, and be useful in the treatment of autoimmune conditions.  
 





(Soiffer, Murray and 
Cochran , et al. 1992) 
Bone marrow transplant N=13 
 
No graft versus host 
disease seen. 
Interestingly, transplant 
was T cell depleted 
(Soiffer, Murray and 
Gonin , et al. 1994) 
Bone marrow transplant N=29 Reduced disease relapse. 




depleted in this study. 




Renal cell carcinoma or metastatic 
melanoma 
N=8 Although a relatively 
high dose was used (7.2 
x 105 iu/kg tds), this 
paper is included to 
show that Tregs may be 
induced at higher doses  
(Zorn, et al. 2006) Cancer N=12 
metastatic 










(Zorn, et al. 2009) Graft versus host disease 
following allogeneic 
hematopoietic stem cell 
transplantation 
N=10 Expansion of Treg 
numbers 
(Koreth, et al. 2011) Chronic graft versus host disease N=29 Treg numbers increased. 
Glucocorticoid use 
reduced. 
(Saadoun, et al. 2011) Hepatitis-C induced vasculitis N=10 8/10 vasculitis 
improvement 




(Hartemann, et al. 2013) Diabetes  Final results to be 
published 




(Castela, et al. 2014) Alopecia areata N=5 4/5 patients had clinical 
improvement 
(Ito, et al. 2014) Healthy subjects N=21 Tregs increased 
(Kennedy-Nasser, et al. 
2014) 
Acute graft versus host disease 
following allogeneic 
hematopoietic stem cell 
transplantation 
N=16 No grade 2-4 GVHD in 
treated patients 
(Truman, et al. 2015) Diabetes mellitus  Mutiple dose dose-
finding trial; Final results 
to be published 
(He, et al. 2016) Lupus  Marked improvement 
(Todd, et al. 2016) Diabetes mellitus  Single dose dose-finding 
trial 
(von Spee-Mayer, et al. 
2016) 
Lupus N=5 Treg numbers 
replenished 
(Medicine 2017) 
Induction of Regulatory t 




















Final results to be 
published. 
 
Table 1.8: Compilation of human trials using low-dose rIL-2 for autoimmune conditions 
 
1.15.1 Low dose IL-2 therapy and B cells 
Although clinical trials using low-dose IL-2 have not specifically looked at its effect on B cells, 
there have been at least two reports of a decrease in circulating CD19 positive B cells during 
treatment (Hartemann, et al. 2013) (Saadoun, et al. 2011). It is not clear what caused this 




secondary lymphoid organs. Alternatively, the reduction in B cells numbers may have been an 
indirect results of reduction in Tfh survival. To this extent, papers have suggested reduction in 
levels of circulating Tfhs in IL-2 treated subjects (He, et al. 2016). It is unknown what 















Over the past decade, there has been a concerted effort to improve the medical 
management of AKI. In the United Kingdom, an important turning point was the publication 
of the National Confidential Enquiry into Patient Outcome and Death report, Acute Kidney 
Injury: Adding Insult to Injury published in 2009 (Stewart, et al. 2009). The publication 
highlighted the widespread prevalence and less than ideal management of AKI and suggested 
future improvement strategies. The impetus from this report and other similar publications 
resulted in clinicians’ increased vigilance towards AKI as well as the generation of novel tools 
such as automated electronic reporting of lab results, which identify patients with worsening 
renal function to optimise kidney care in a timely fashion (Breighner and Kashani 2017) 
(Wilson 2017).  
While prevention of AKI can no doubt help patients, there remains a cohort of 
patients for whom AKI and subsequent renal scarring resulting in chronic kidney disease are 
inevitable in spite of optimum treatment. For example, a review of previously published data 
suggests that despite almost constant monitoring, between 20 and 50 percent of patients in 
an intensive care setting will develop AKI (Case, et al. 2013). This situation begs the question 
why in spite of the high prevalence of AKI, the mainstay of treatment in most cases for the 
condition has remained unchanged for many years: This typically consists of the triad of 
optimising fluid management, withdrawing nephrotoxic medications and treating any 




amelioration of AKI by manipulation of the immune response in animal models (as discussed 
earlier), there remains no widely available or commonly used therapy specifically directed 
towards AKI in humans. 
Relatively little work has been done on B lymphocytes and AKI. Indeed previous work 
on B cells has focused on their role in adaptive immunity as antibody-producers, but there is 
increasing evidence that B cells have a much broader functional remit. For example, innate 
B1a cells located predominantly in the spleen produce granulocyte macrophage colony-
stimulating factor (GM-CSF) during Gram-negative sepsis and induce distant neutrophil 
expansion and mobilisation from bone marrow and limit bacteraemia (Rauch, et al. 2012). 
Others have shown that B cells can also exert local effects attracting monocytes into 
myocardial tissue following acute myocardial infarction (Zouggari, et al. 2013).  
Here, we show that there is re-distribution of immune cells in the early hours of AKI. B 
cells, and in particular CD11b+ B cells move from the spleen and from bone marrow into the 
kidney where they produce CCL7 attracting other immune cells. Cell-intrinsic CD11b 
deficiency reduces the entry of B cells into the kidney while blockade of CCL7 using a 
monoclonal antibody ameliorates disease. On the other hand, Siglec-g knockout mice, which 
have proportionally higher numbers of B1 and CD11b+ B cells relative to their wildtype 
counterparts, are more prone to AKI. Siglec-g is an inhibitory molecule found almost 
exclusively on B cells, and intravenous infusion of sialic acid, a Siglec-g agonist, ameliorates 
AKI. Finally, analysis of human kidneys from deceased donors deemed unsuitable for 
transplantation shows that CCL7 transcript levels are increased in kidneys which have AKI 
thus showing clear human relevance to our murine studies.  Together our data suggest that 
blockade of CD11b or CCL7 or engagement of Siglec-g/10 using sialic acids represent 
potential novel therapeutic avenues for the treatment of AKI.  
 
2.1 Results  
To investigate the systemic immune response during AKI, there are a number of murine 
models of AKI including cisplatin- and folic acid-induced AKI as well as renal artery clamping 




discussed in section 1.12.8. For the majority of experiments in this chapter, in order to keep 
consistency between the experiments, we used folic acid-induced acute kidney injury.  
 
2.1.1 Bone marrow neutrophil mobilisation during AKI  
To investigate the systemic immune response in AKI, we performed flow cytometric analysis 
of bone marrow (tibial and femoral) aspirates.  Neutrophil numbers were analysed 15 hours 
following administration of varying amounts of folic acid in order to produce variable severity 
of AKI. We observed a negative linear relationship between the severity of AKI, as measured 
by serum urea, and the proportion of neutrophils in the bone marrow (figures 2.1 and 2.2). 
The reduction of bone marrow neutrophils was mirrored by an increase in circulating blood 
and kidney neutrophils (figures 2.2 and 2.5) supporting the view that during AKI a systemic 




Figures 2.1 (left) and 2.2 (right). Percentage of bone marrow and blood 
neutrophils among CD45 positive leucocytes against serum urea. All analysis of 
blood was done using cardiac bleeds. Mice were a mixture of males and 
females between 6 to 12 weeks old. Mice were culled and analysed 16 hours 
after varying weight-adjusted intraperitoneal folic acid injection. Neutrophils 
were defined as the population of single, CD45-positive, Ly6C-high and GR1-
high events on flow cytometry. Note a viability stain was not part of the gating 
strategy as most neutrophils die rapidly both in and ex vivo. Two experiments 




clotting). Linear regression. R2 represents goodness of fit and p value 
represents whether the slope is significantly non-zero.  
 
Throughout this series of experiments, in order to distinguish intravascular and 
extravascular leucocyte in the kidneys, we employed a technique in which mice were injected 
intravenously via a tail vein with a fluorochrome-labelled anti-CD45 antibody one minute 
prior to culling in a carbon dioxide chamber (figure 2.3). During laboratory processing, tissues 
were stained again with an anti-CD45 antibody conjugated to a different fluorochrome. Flow 
cytometry analysis showed that leucocytes which were doubly positive for both intravenous 
and ex vivo-applied CD45 antibody were from the intravascular compartment (figure 2.4). 
Those cells not in the vasculature were singly positive for ex vivo-applied CD45 antibody. To 
confirm that the intravenous injection was successful, blood leucocytes from all mice were 
also analysed. Consistently, more than 90% of blood leucocytes were labelled with 
intravenous anti-CD45 antibody. Samples were excluded from any further analysis if blood 
leucocytes were not successfully labelled as distinction between intravascular and 
extravascular leucocytes was not possible. Using this approach, usually only a negligible 
proportion of intravascular cells were stained if, for example, there was extravasation of the 




Figure 2.3 (left). Diagram showing injection of FITC anti-CD45 antibody 




plot of CD45 with two different fluorochromes showing two different 
populations of intravascular and extravascular leucocytes in the kidney.  
 
Perhaps one critique of this technique is that there may be some degree of ‘leakage’ of the 
intravascular anti-CD45 antibody into the extravascular space. However, it has been shown in 
a number of other works that this leakage is minimal (Anderson, et al. 2014). In future, one 
potential method of assessing the extent of such leakage may be to cull mice at different time 
points following intravenous injection of anti-CD45 antibody (for example, 1, 2, 5, 10, 60 
minutes) and examine the kidneys using confocal microscopy. Intravascular and extravascular 
cells may then be counted manually.  
 
 
Figure 2.5: Number of extravascular kidney neutrophils against serum urea. 
Mice were a mixture of males and females between 6 to 12 weeks old and 
were culled and analysed 16 hours after varying weight-adjusted 
intraperitoneal folic acid injections. Neutrophils were defined as the 
population of single, in vitro stained pan CD45 positive, in vivo stained 
intravascular CD45 negative, Ly6C high and GR1 high events on flow cytometry. 
Two experiments combined. N=13 mice in total. Linear regression. R2 
represents goodness of fit and p value represents whether the slope is 
significantly non-zero. (Note: This experiment is completely independent from 




for differentiating intravascular and extravascular leucocytes was not yet 
developed when the earlier experiments were done.) 
 
 Though these data show the dynamics of neutrophils in an AKI severity-dependent 
manner, there are nonetheless some caveats which may in future merit further investigation. 
First, in the experiment whose data are shown in figures 2.1 and 2.2, while we chose mice 
which were between 6 and 12 weeks old, we made no effort to balance the number of males 
and females. Additionally, a degree of genetic drift may be present between the individual 
mice as the mice used were not littermates and often were the simply unneeded wildtype 
siblings of genetically modified mice. For reasons of expense, we have not fully genetically 
sequenced these mice to assess comprehensively for genetic drift. It was felt at the time of 
the experiment that it would be more ethical and more economical to use these mice in 
experiments and derive some data from them rather than purchasing further mice from 
outside providers or re-deriving multiple generations of backcrossed wildtype mice. 
Moreover, one could argue that the variation in background of these mice in fact reinforces 
the strength of these data given that even with some variable genetic backgrounds, a 
statistically significant trend was observed.  
 
2.1.2 Dynamics of B cells during AKI 
We next investigated the global dynamics of B cells, T cells, and neutrophils in the spleen, 
blood and kidney in the early stages of AKI (figure 2.4). AKI was again induced by 
administration of folic acid. We observed that the splenic B cell count reduced by half with a 





Figure 2.6. Global dynamics of B cells, T cells, neutrophils and monocytes 
during early stages of AKI. Following folic acid induced AKI, mice were culled at 
3, 6 and 15 hours. Flow cytometry counting beads were used to estimate the 
total number of cells in the whole organ. Three experiments combined. N = 16 
in total. Significance calculated using a non-paired parametric two-tailed T-test. 




0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, NS not significant. Error bars 
represent standard error of the mean (SEM).  
 
2.1.3 CD11b and its role in B cells 
We examined the blood more closely to assess the phenotype of trafficking B cells. Strikingly, 
whereas in the normal healthy state, about 1% of B cells were CD19+B220-, by 15 hours after 
AKI induction, approximately 20% of all B cells were CD19+B220- (figures 2.7 and 2.8).  
 
     
 
Figure 2.7 (left). Flow cytometry analysis of blood taken from untreated and 
folic acid treated mice. Gated on single, viable, CD19 positive events. Figure 2.8 
(right). Quantification of CD19+B220- B cells in the blood. Error bar represents 
standard error of the mean. N=13 in total (six given vehicle and seven given 
folic acid). Mice were a mixture of males and females between 6 to 12 weeks 
old. Mice culled and tissue processed 16 hours following insult. Statistical 
significance calculated using a non-paired parametric two-tailed T-test. Error 
bars represent standard error of the mean (SEM). 
 
To confirm that these cells were indeed B cells, we stained for CD20, an additional B 
cell surface marker, as well as other markers which are traditionally considered to be more 
myeloid cell surface markers such as CD11b and GR1. The CD19+B220- subset expressed 
CD20 at levels similar to other CD19+B220+ B cells (figure 2.9). Given their high expression of 
CD5 and CD11b, we concluded that the CD19+B220- blood B cells were enriched in CD11b+ B1 








Figure 2.9. CD19+B220- B cells express high levels of CD20, CD5 and CD11b. 
Gated on single, viable events. Mice culled and tissue processed 16 hours 
following insult. Blue histograms are representative of CD19+B220- events and 
the red histograms representative of CD19+B220+ events.  
 
We examined the distribution of these CD11b+CD19+B220- B cells within the kidney. In the 
kidneys of mice treated with vehicle, less than 10% of B cells in the extravascular space 
expressed CD11b (figure 2.10). During AKI there was a significant increase in 
CD11b+CD19+B220- B cells. Indeed, in the extravascular space, more than 30% of B cells 
expressed CD11b during AKI. 
 
 
Figure 2.10. Percentage of CD11b+ B cells within the intravascular and 
extravascular spaces during health and AKI. Gated on single, viable, CD19 




N=7 in total (2 and 5 mice in each respective condition). Significance calculated 
using a non-paired parametric two-tailed T-test. Error bars represent standard 
error of the mean (SEM). 
 
Given that CD11b along with CD18 forms part of the MAC-1 complex used by myeloid cells 
to tether to the vasculature during extravasation into interstitial spaces, and that one of the 
ligands for MAC-1 is ICAM which is known to be highly expressed in the kidneys during AKI, 
we hypothesized that B cells also use CD11b for a similar function (De Greef, Ysebaert and 
Persy, et al. 2003). To investigate this hypothesis, a competition assay was set up in which 
μMt mice lacking mature B cells were injected with 5x106 wildtype CD45.1 B cells and an 
equal number of CD11b-/- CD45.2 B cells (figure 2.11). 24 hours after B cell transfer, AKI was 
induced with folic acid. The kidneys were harvested after 16 hours. In the extravascular 
space of the kidneys, there were significantly more wildtype B cells than knockout cells by a 
ratio of more than two to one (figure 2.12). In contrast, in the intravascular space, this ratio 




Figure 2.11. Schematic diagram of the experimental setup for injection of 
CD11b+/+ and CD11b-/- B cells before AKI. μMt mice were injected with 5x106 
CD11b+/+ CD45.1 wildtype and 5x106 CD11b-/- CD45.2 B cells. 24 hours after 
injection, AKI was induced with folic acid. 16 hours later, intravenous FITC anti-







Figure 2.12. Extravascular and intravascular wildtype and CD11b-/- B cells 
following AKI. N=12. Significance calculated using a non-paired parametric two-
tailed T-test. 
 
A number of comments can be made about this set of experiments. First, there has been 
some controversy regarding the presence of CD11b positive B cells as illustrated in a number 
letters to the editor (Reynaud and Weill 2012). Specifically, it has been suggested that the 
initial discovery by Griffin and colleagues that this population may in fact be a sorting artefact 
(Griffin and Rothstein 2011). It was suggested that these events may represent ‘doublets’ of 
two attached cells, for example, between a B cell and a myeloid cell such as a monocyte. 
However, during our experiments we meticulously gated out doublets. Moreover, there have 
been other subsequent publications which have suggested the existence of CD11b positive B 
cells in other experimental models such as autoimmune hepatitis (Liu, et al. 2015). To 
ultimately answer these questions in future, single-cell RNA-seq may be useful to understand 
better the transcriptomic signature of this cell population.  
 Second, the use of μMt mice as a carrier for these B cells may not replicate an 
immunologically ideal model if the goal is to recapitulate a mouse which has both CD11b+/+ 
and CD11b-/- B cells in equal numbers. For example, I am aware that after a few weeks μMt 
mice which have been given B cells no longer have detectable B cells, though this was not the 
case in our three day experiment (Scott 2018). Moreover, μMt mice do not have a completely 
normal myeloid population as B cells may regulate and promote their development. However, 
for the purposes of this experiment, which was to assess the ability of B cells to enter the 





2.1.4 CCL7 and B cells 
The role of these B cells remained to be determined. We hypothesized that B cells may be 
important producers of chemokines that mobilise and activate other immune cells. To screen 
for potential candidate cytokines, we induced AKI in both wildtype and μMT mice and 
analysed their whole kidney lysate by qPCR for cytokine transcripts (figure 2.13). CCL7 was 
significantly lower in mice lacking B cells and there was a less substantial difference in CCL5, 
CXCL1 and CXCL2 in μMT compared to wildtype mouse kidneys. We focussed primarily on 




Figure 2.13. qPCR of whole kidney lysate from wildtype and μMt mice to 
screen for significant differences in cytokine production following folic acid-
induced AKI. N=6 in total (3 per group). Mice culled and tissue processed 16 
hours following insult. Significance calculated using a non-paired parametric 
two-tailed T-test. Error bars represent standard error of the mean (SEM).  
 
To confirm that B cells have the potential to produce CCL7, we negatively isolated 
splenic B cells then co-cultured them with various stimuli and measured the supernatant 
cytokine concentrations by ELISA (Figure 2.14). There was a significant increase in CCL7 
following stimulation with DAMPs such as HSP70 and following BCR cross-linking using hen 
egg lysozyme (HEL) in HEL-IgM-BCR transgenic (MD4) mice. CXCL2 was also produced 







Figure 2.14. CCL7 production following stimulation with a TLR-ligand, DAMP 
and BCR antigen by 5x105 negatively-isolated B cells over 60 hours. B cells 
isolated from a single murine spleen. Supernatant measured by ELISA. Both 
experiments performed twice with similar results. Significance calculated using 
a non-paired parametric two-tailed T-test. Error bars represent standard error 
of the mean (SEM). 
 
To assess the role of CCL7 in AKI in vivo, anti-CCL7 neutralising antibody was injected at the 
same time as folic acid. CCL7 neutralisation significantly reduced AKI severity as indicated by 




Figure 2.16 (left). Diagram of protocol for injection of anti-CCL7 neutralising antibody 
along with folic acid. Figure 2.17 (right) Quantification of serum urea 16 hours 
following AKI induction. Two experiments combined. N=12 in total (2, 5 and 5 in each 





As with experiments discussed in the previous section, the use of μMt mice can be 
problematic given their global immunological aberrations. However, in these experiments, 
μMt mice have been used as a screening tool to narrow down potential cytokines which 
might be useful to assess more closely. Another method of conducting the experiments 
described in figure 2.13 is to deplete B cells using a depleting antibody against CD19 or CD20, 
followed by folic acid administration. However, until recently, these antibodies have been 
very costly and difficult to access.  
Our data demonstrate that CCL7 blockade does ameliorate AKI in this murine model. 
This is not a complete blockade of pathology, in that urea levels do not return to normal 
levels, but they are substantially reduced compared to animals receiving the isotype control 
antibody. The extent to which this blockade was pharmacologically complete, i.e. that all 
CCL7 in the mouse was bound by antibody, was not formally assessed.   
 Finally, future investigations will need to look at the signals necessary for this B cell 
mobilisation and activation in the context of AKI. B cells may be directly responding to DAMPs 
or to cytokines released by myeloid cells in response to DAMPs. Our experiments show that 
BCR cross-linking induces CCL7 production, and this may occur in the presence of multimeric 
T-independent antigen that can be found on the surface of necrotic cells.   
 
2.1.5 Siglec-g-/- mice with increased B1 cells and their susceptibility to AKI  
Since the blockade of CCL7 led to amelioration of AKI, we hypothesized that mice with 
increased numbers of B1 cells might have worse AKI. Siglec-g is a protein found almost 
exclusively on B cells (figure 2.18). Siglec-g deficiency results in a fourfold increase in B1 cells 
in mice (Hoffmann, et al. 2007). In our analysis, flow cytometric analysis of splenocytes from 
Siglec-g-/- showed an approximately seven-fold increase in CD19+B220- B cells (figure 2.19). 
Thus Siglec-g deficient mice seemed a useful model to test the effects of excess B1 cells in 
vivo. In addition to an increase in the B1 cell population, Siglec-g-/- B cells also have a lower 
threshold of activation given the protein’s inhibitory function. We concluded that this feature 






Figure 2.18. Representative flow cytometry histograms illustrating expression 
of Siglec-g in different immune cells. Blue histograms represent isotype control.  
 
 Low-dose intraperitoneal folic acid (150mg/kg) was given to Siglec-g+/+ wildtype and 
Siglec-g-/- mice. We found that in younger mice which were under 25 grams, there was no 
difference in serum urea levels (figure 2.20). However, above 25 grams, wildtype mice 
showed only a small urea rise after folic acid induced AKI, while Siglec-g-/- mice had 
significantly higher urea levels. The knockout mice had higher numbers of neutrophils in the 




























Figure 2.19 Representative flow cytometry plot of splenic CD45 positive 




Figure 2.20. Serum urea concentrations from mice given low-dose folic acid 
induced AKI. Mice culled and tissue processed 16 hours following insult. N=22 















Figure 2.21. Extravascular renal CD19+B220- B cells following low-dose folic 
acid induced AKI. Mice culled and tissue processed 16 hours following insult. 
N=22 in total (13 and 9 in each group). Significance analysed using a 
parametric unpaired two-tailed T test. Error bars represent standard error of 
the mean (SEM).  
 
We repeated experiments in two other models of AKI: cisplatin-induced AKI and temporary 
surgical clamping of the renal pedicle. Following cisplatin-induced AKI, urea levels were 
approximately four times greater and weight loss was more than 5 per cent greater in the 
Siglec-g-/- group (figure 2.22). Histological sections of the kidney were viewed using confocal 
microscopy and stained with a GR1 antibody. GR1 positive cells per visual field were 
significantly greater in number in Siglec-g-/- mice following AKI. Haematoxylin and eosin staining 
of fixed tissue was analysed in a blinded fashion by a trainee nephrologist (figure 2.22 and 2.23). 
Tissue was scored on the basis of tubular necrosis, tubular dilatation and cast formation, which 








Figure 2.22 (top) Cisplatin-induced AKI in Siglec-g-/- mice. Quantification of 
serum urea, weight loss, ATN score and neutrophil infiltration in the kidney. 
Figure 2.23 (bottom) Representative histological sections of kidney (right). 
N=12 in total. Significance analysed using a parametric unpaired two-tailed T 
test. Error bars represent standard error of the mean (SEM). 
 
Although cisplatin remains a commonly used experimental tool to induce AKI, the 
agent has a number of disadvantages. For example, given its chemotherapeutic mode of 
action of inhibiting DNA replication by forming adducts between the cisplatin molecule and 
DNA, the nephrotoxin could have immunological side-effects which may not be helpful in 
investigating the immune response during AKI. Therefore, another model of AKI was used. In 
collaboration with our surgical colleagues, Mr Kourosh Saeb-Parsy and Mr Jack Martin, 
laparotomised mice underwent temporary renal pedicle clamping for 45 minutes under 
general anaesthetic. As observed in the cisplatin model, Siglec-g-/- mice had similarly higher 
levels of urea and increased neutrophil levels in the kidney when this surgical approach was 










Figure 2.24: Surgical renal pedicle clamping in AKI. Quantification of serum 
urea and neutrophil infiltration by flow cytometry. N=7 in total (3 and 4 in 
respective groups). Neutrophils as a percentage of all viable events. Please 
note this experiment was done before the technique for labelling intravascular 
and extravascular leucocytes was developed. This experiment was conducted 
once. Mice culled and tissue processed 16 hours following insult. Significance 
analysed using a parametric unpaired two-tailed T test. Error bars represent 
standard error of the mean (SEM). 
 
 A number of caveats to this set of experiments should be mentioned. The main 
consideration is that the wildtype mice used in these experiments were bred in parallel but 
were not sibling littermates. As with other experiments discussed in this thesis, there may be 
some degree of genetic drift that has taken place which we have not actively analysed. In 
addition, as the birthdates are not identical between compared mice in such a model, AKI 
may be induced at slightly different timepoints in the mouse’s life. We did not use littermate 
siblings for a number of reasons including cost and efficiency as mice heterozygous in the 
Siglec-g gene would need to be culled as they would not be required for these experiments 
and larger numbers of wildtypes or knockout mice could be generated (especially if bred as a 





2.1.6 Sialic acid and its amelioration of AKI  
One of the agonist ligands for Siglec-g and other Siglec proteins is sialic acid. In humans, the 
normal physiological level of sialic acid is about 68mg/100ml (Carter and Martin 1962). We 
hypothesized that administration of intravenous sialic acid immediately prior to giving 
intraperitoneal cisplatin to wildtype mice during AKI may ameliorate the condition. Using a 
naturally occurring sialic acid, Neu5AC, during AKI, we observed reduced urea levels as well 




Figure 2.25: Intravenous sialic acid administration immediately prior to 
intraperitoneal cisplatin-induced AKI ameliorates disease severity.  
Quantification of serum urea and neutrophil infiltration. N=11 in total (5 and 6 
mice in each respective group). Neutrophils as a percentage of all viable cells. 
Please note this experiment was done before the technique for labelling 
intravascular and extravascular leucocytes was developed. Mice culled and 
tissue processed 16 hours following insult. Experiment repeated twice. 
Significance analysed using a parametric unpaired two-tailed T test. Error bars 
represent standard error of the mean (SEM).  
 
 This experiment poses a number of questions which remain unanswered. For example, 
is it possible to know whether the effect of sialic acid is specific to Siglec-g? Even more 
specifically, is the effect specific to Siglec-g on B cells? The causality remains unclear. To 




would be to test its effects in Siglec-g knockout mice. To answer whether Siglec-g specifically 
affects B cells, it would be necessary to use a mouse with a B cell specific deficiency of Siglec-
g by employing, for example, a lox-cre construct. In future, we also plan to analyse the 
numbers and characteristics of the infiltrating B cells when sialic acid is given.  
 
2.1.7 Human AKI kidneys and expression of CCL7 and CXCL2 
To assess the relevance of these findings in human disease, we investigated kidney samples 
from deceased transplant donors (Table 2.1). The demographic details were collected (Table 
2.1) and all samples were from the renal cortex. They included 8 patients without AKI and 7 
patients with AKI. Whole kidney lysates were analysed by qPCR for CCL7, CXCL2 and CD19. 
CCL7 was undetectable in all but one non-AKI kidney sample (figure 2.26). All but two AKI 
kidneys had high levels of CCL7 transcript. Significant differences were observed in CXCL2 
levels. CD19 transcript levels, which represent B cell infiltration, were not significantly 








Cause of death 
10 57/Male 52 Intracranial haemorrhage  
14 78/Female 50 Intracranial haemorrhage 
35 59/Female 48 Hypoxic brain injury from choking 
37 70/Male 57 Fall and hypoxic brain injury 
41 48/Male 31 Pneumonia 
43 77/Male 54 Aortic dissection 
65 73/Female 52 Intracranial haemorrhage 
121 69/Female 44 Intracranial haemorrhage 
20 55/Male 210 Cardiac arrest (cause unknown) 
18 57/Female 167 Cardiac arrest (cause unknown) 
52 73/Male 180 Unknown 
62 61/Male 230 Cardiac arrest (cause unknown) 
67 71/Male 174 Hypoxic brain injury 
77 36/Male 145 Intracranial haemorrhage 





Table 2.1. Demographic details of the patients. Blue font represents donors 
with no AKI according to pre-terminal serum creatinine and red font represents 




Figure 2.26 CCL7, CXCL2 and CD19 transcript levels respectively from non-AKI 
and AKI cadaveric donor kidneys. N=15 in total (8 and 7 donors in each 
respective group). Significance analysed using a parametric unpaired two-tailed 
T test.  
 
 The significance of these data is that they begin to recapitulate in humans murine 
findings described earlier. Clearly, even within the small number of subjects in this study, 
there are greater amounts of CCL7 and a trend towards greater amounts of CD19 transcripts 
indicative of B cell infiltration into human kidneys with AKI.  
It should be mentioned that there are a number of small caveats to these data which 
do not detract from the central thrust of the argument but are nonetheless worth discussing. 
First, it is not clear that patients who have recently sustained a severe illness such as non-
recoverable intracranial haemorrhage and subsequently died, even when serum creatinine is 
within the normal range, can be assumed to have normal kidneys. For example, hormonal 




Ideally, it will be necessary in future to derive corroborative data from, for example, biopsies 
taken from normal kidneys such as during a live-donor kidney transplant.  
Second, the samples were not collected wholly randomly. For example, members of 
the laboratory may have decided to turn down offers of kidneys for research for a whole 
range of reasons including long ischaemic times or severe AKI. In other words, kidneys which 
may have suffered from excessive ischaemic injury – and are therefore the kidneys most 
appropriate for this study – may have been inadvertently excluded. Indeed, of over 200 
kidneys collected, only a handful had AKI. All kidneys which sustained AKI and were snap-
frozen, and therefore suitable for processing, were included in this study. Control samples 
were chosen from the first eight samples found with serum creatinine of less than 60 μmol/L.  
Third, we do not yet have direct evidence that, in human kidneys, the primary source 
of CCL7 is from extravascular B cells within the kidney. To ascertain this, I have started an 
experiment to process human kidney tissue by flow cytometry using an intracellular CCL7 
antibody. Initial experiments show that B cells appear to produce the greatest amount of 
CCL7 of all leucocytes, however, further investigation is necessary to confirm these findings.  
Finally, to investigate whether CCL7 has the potential to be a biomarker of AKI, we 
obtained urine from healthy subjects and hospital in-patients who had AKI. Consistent with 
our findings from whole kidney transcripts, CCL7 concentrations were higher in the urine of 







Figure 2.27. CCL7 concentration in the urine from healthy and AKI subjects 
measured by ELISA. Significance analysed using a parametric unpaired two-
tailed T test. Error bars represent standard error of the mean (SEM).N=49 in 
total.  
 
 While it is tempting to infer from these data that CCL7 may represent a potential 
biomarker of AKI, this will require further validation due to a number of limitations of the 
current dataset we have generated. Firstly, we selected CCL7 for measurement in a 
hypothesis-driven manner based on murine data. However, there are many molecules 
present in urine and an unbiased assessment using, a broader, proteomic or metabolomic 
approach might identify additional more sensitive and specific biomarkers. 
Secondly, during most phases of AKI, urine concentration can be deranged as a result 
of increased tubular permeability and lower osmolarity of the renal interstitial fluid. As a 
result, the vast majority of molecules may be more dilute. To adjust for this, other 
investigators have simultaneously measured urinary creatinine which can provide a surrogate 
marker for urinary concentration. For example in clinical practice, urinary albumin levels have 
historically been measured over a 24 hour period (which can be practically tedious for 
patients) but this has now largely been replaced by measurement of the ratio of albumin to 
creatinine in a spot urine sample.  Thirdly, our data would require validation in an 
independent, preferably larger, sample collection. 
 
2.2 Discussion 
In summary, observation of B cell dynamics during the early hours of AKI suggests they have 
an important role in mobilising other immune cells into the kidneys. Within 16 hours 
following induction of AKI, a large number of CD11b+CD19+B220- B cells appear in the 
circulation and employ the MAC-1 complex to enter inflamed renal tissue. After entering the 
kidneys, B cells release CCL7 which has the potential to attract a range of myeloid cells 
receptive to this cytokine. Blockade of CCL7 can ameliorate disease. Conversely, deficiency of 
Siglec-g, an inhibitory protein found predominantly on B cells, leads to an excess of B1 cells 




agonist, sialic acid, ameliorates AKI. Finally, analysis of human kidneys with AKI shows an 
increase in CCL7 suggesting there is clear human relevance to these findings.  
 These findings are in concordance with previous studies which have shown that CCL7 
from B cells is crucial in attracting myeloid cell populations during myocardial infarction 
(Zouggari, et al. 2013). Additionally, just as the lack of Siglec-G worsened AKI outcomes in our 
study, others have shown the absence of Siglec-g exacerbating B cell dependent autoimmune 
conditions such as arthritis (Bökers, Urbat, et al. 2014). 
 
2.3 Future plans 
A number of additional experiments would be useful to build on this work. In humans, we 
know there is an activated form of CD11b where a conformational change has taken place. In 
fact, an antibody has been developed which specifically identifies activated CD11b in human 
cells (Diamond and Springer 1993). In mice, however, an antibody has not yet been 
developed which identifies the activated form of this surface protein. It would be useful to 
have such a tool to assess whether, during AKI, B cells change their CD11b conformation. 
Indeed conformational change may explain why there are more CD11b+ B cells in the renal 
vasculature during the healthy state.  
 Moreover, it may be that CD11b+ is in some way involved in cytokine signalling. 
Previous publications have suggested MAC-1 has downstream effects on the transcription 
factor NF-κβ. Experiments not described here have not shown a significant increase in CCL7 
levels following stimulation with either or both CpG and soluble ICAM. However, given that 
one of the most potent inducers of CCL7 is BCR antigen as shown in figure 2.14, perhaps 
concomitant stimulation with antigen and ICAM may induce greater amounts of CCL7. In vivo, 















The public health burden of autoimmune diseases and organ transplantation is substantial 
and increasing. Though it is difficult to generate accurate statistics due to discrepancies in 
classification, one recent publication conservatively estimates that in the United States alone 
there were approximately 14.7 million people diagnosed with some form of autoimmune 
disease, an increase from 9 million 15 years previously (Hayter and Cook 2012) (Jacobson, et 
al. 1997). Organ transplants have also progressively increased over the past decade. In 2016, 
33,600 organ transplants were undertaken in the United States – a 20 percent increase from 
five years previously (United Network for Organ Sharing 2017). The majority of patients with 
autoimmune disease and virtually all patients with organ transplantation require some form 
of immunomodulatory therapy for disease control and prevention of immunological rejection 
respectively.  
The potential wide-ranging role of B-regs in autoimmunity and transplantation, as 
discussed in the introduction, begs the question whether this cell type can be effectively 
harnessed therapeutically in humans. The majority of studies to date have relied on murine 
models involving B-reg cellular transfer followed by observation of the effect on disease 
severity. However, directly translating these models into human treatments is difficult as 
cellular therapies are labour-intensive and costly (Abou-El-Enein, Bauer, Medcalf, Volk, & 
Reinke, 2016). Additionally, other questions such as the long-term efficacy and safety of 
cellular therapies remain unanswered. For example, how long do ex vivo-induced B-regs 




transformation? At the same time, inducing B-regs in vivo through pharmacological means 
has not been adequately explored. From an economic and regulatory point of view, 
repurposing of previously approved drugs may be an attractive alternative to developing new 
therapies.  
With these clinical and scientific problems in mind, two strands of research were 
planned. First, we noted transcriptional studies by others demonstrating high expression of 
CD25, the alpha component of the trimeric IL-2 receptor, on IL-10-producing B-regs (van de 
Veen, et al. 2013) and speculated whether IL-2 may play a role in modulating IL-10 
production and how the cytokine may fit with our understanding of the signalling pathway. 
Second, given the recent renewed interest in low-dose recombinant human IL-2 therapy as a 
potent inducer of regulatory T cells in a number of human clinical trials, including at least four 
local trials in Cambridge, England, an analysis of patients’ peripheral blood samples was 
undertaken to see whether low-dose IL-2 therapy augments B-reg populations.  
 We hypothesized the following:  
1. Some B cells express the trimeric IL-2 receptor and can be 
receptive to IL-2. 
2. Given that downstream of the IL-2 receptor is the PI3k pathway, 
engagement of the IL-2 receptor may skew B cells towards to a 
more anti-inflammatory phenotype. 
3. In-vivo administration of low dose IL-2 may induce regulatory B 
cells in mice and humans with autoimmune conditions and may 
provide a novel treatment option for a range of conditions where 
regulatory B cells have been implicated.  
 
3.1 Results 
3.1.1 IL-2 and IL-10 production in B cells  
Reanalysis of publicly available data suggested higher CD25 transcript levels in IL-10 





Figure 3.1. Interleukin receptors sharing the common IL2Rγ chain (CD132) on 
IL-10 producing regulatory B cells over non regulatory B cells. Raw gene 
expression data were extracted from a publically available transcriptomic 
dataset (GEO accession number GSE35002) generated by (van de Veen, et al. 
2013) in which IL10 positive and negative B cells were transcriptionally 
characterised using gene mircoarrays. Each column represents an independent 
sample of regulatory B cells. Brightness of red represents log-fold increase 
(brightness of green represents log-fold decrease) in RNA over non-regulatory 
B cells.  N = 6 healthy donors. 
 
To assess whether these RNA data correlate to actual protein expression, we conducted a 
number of flow cytometry experiments on B cells. In human peripheral blood, basal surface 
CD25 expression was detectable in only 2% of B cells (Figures 3.2 and 3.3). However, 
following activation in vitro with the TLR9 ligand CpG alone, or with CD40 ligand, we observed 
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Figure 3.2 (top). Human blood B cell expression of CD25 following overnight 
stimulation with TLR and CD40 ligands. Leucocytes were isolated through a 
histopaque gradient. Figure 3.3 (bottom). Quantification of percentage of CD25 
positive human blood B cells following stimulation. Single healthy blood donor. 
Experiment conducted three times with similar results. Significance calculated 
using a non-paired parametric two-tailed T-test. Asterisks represent the 
following p values: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, NS 
not significant. Error bars represent standard error of the mean (SEM).  
 
Since B cell activation takes place in secondary lymphoid organs, and B cells in these organs 
differ in their functional characteristics and their responsiveness to immunomodulation, we 
also investigated human splenic B cells which were donated after death. We found an 
increase in the proportion of B cells that expressed CD25 following stimulation with CpG and 
CD40L, from 7% at baseline to 28% post-stimulation (p<0.001, figures 3.4 and 3.5). Similarly, 
in murine splenic B cells, CD25 expression was markedly increased following stimulation with 
TLR ligands and CD40 ligation (figures 3.6 and 3.7). It should be noted that in murine in vitro 
stimulation experiments, we used LPS as well as CpG and CD40 ligand. In human experiments, 
we did not use LPS, as TLR4 is minimally expressed by unstimulated human B cells (Bourke, et 
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Figure 3.4 (top). Human splenic B cell expression of CD25 following overnight 
stimulation with TLR and CD40 ligands. Figure 3.5 (bottom). Quantification of 
percentage of CD25 positive human splenic B cells following stimulation. 
Significance calculated using a non-paired parametric two-tailed T-test. Error 
bars represent standard error of the mean (SEM). Single human spleen. 




Figure 3.6 (top). Murine splenic B cell expression of CD25 following overnight 
stimulation with TLR and CD40 ligands. Figure 3.7 (bottom) Quantification of 
percentage of CD25 positive murine splenic B cells following stimulation. 
Significance calculated using a non-paired parametric two-tailed T-test. Error 
bars represent standard error of the mean (SEM). Single murine spleen. 
Experiment conducted three times with similar results.  
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Together these data show that in both humans and mice at rest, a small proportion of 
peripheral and splenic B cells have the capacity to respond to IL-2, but that following 
activation following conventional stimuli, an upregulation of CD25 significantly increases this 
number.  
On reflection, it could be argued that one weakness in these B cell stimulation 
experiments (figures 3.2-3.6) is that samples have been derived from a single human or 
mouse and that replicates are experimental and not biological, though each of these 
experiments have been conducted multiple times. Here, biological replicates were not 
undertaken for a couple of reasons: First, though the overall pattern of CD25 expression 
following stimulation does not differ between individuals, the actual proportional values do 
differ. For example, following CpG stimulation, B cells from some subjects expressed greater 
amounts of CD25 than other subjects at baseline without stimulation and this discrepancy 
was accentuated when stimulated with ligands such as CpG and CD40 ligand. Therefore, 
given this variability and given the cost and time involved to achieve statistical significance 
these larger experiments were not conducted. Moreover, given that the purpose of these 
experiments was simply to prove that B cell had the potential to express CD25 and not to 
quantify a population average it did not seem appropriate to pursue leucocyte samples from 
a larger cohort of patients. Finally as human spleens were donated at irregular and 
unpredictable times, it was not possible to process the samples simultaneously. As a result, 
further discrepancy between samples would be introduced by repeating the experiment at 
different times.  
Another question which these experiments do not answer is which types of B cells 
most avidly upregulate their CD25 expression. We did not co-stain for other surface markers 
as these often change after stimulation. One potential future experiment would be to pre-
sort different B cell subsets and to stimulate them and then stain for CD25. 
 
3.1.2 Difficulty with assessing CD25 on human B cells 
Interestingly, although we observed little CD25 on the surface of unstimulated B cells, this 
may not be the case in vivo. Suspicion that there may be more CD25 expression than 




group which showed significantly greater amounts of CD25 expression by unstimulated B 
cells. This group had analysed leucocytes in a flow cytometer after strong red cell lysis but no 
histopaque gradient. To assess this further, we conducted a head-to-head analysis. Human 
blood was taken from a subject and mixed with citrate and red cell lysis. Even if the red cell 
lysis was subjectively inadequate with the sample still retaining a rosé coloured appearance, 
the cells were stained for CD19 and CD25. What would normally be considered an excessive 
number of events were collected on flow cytometry on the assumption that the majority of 
events would be irrelevant red blood cells. In a second sample, leucocytes underwent a 
histopaque gradient followed by red cell lysis and antibody staining. A comparison was made 
between these two different preparations.  
Two observations can be derived from this experiment (figure 3.7). Firstly, in samples 
taken from the same subject, there was considerably more CD25 in unstimulated cells than 
shown above (figure 3.2 to figure 3.4). Secondly, there was considerably less CD25 following 
the longer and more strenuous leucocyte preparation involving a histopaque gradient.  These 
observations led us to test whether CD25 was released from stimulated splenic human B cells 
which had been negatively isolated (figure 3.8). The supernatant from these cells was 
analysed by ELISA. Indeed, large amounts of soluble CD25 were detected.  
 
  
 Figure 3.7. Representative flow cytometry plots of CD25 expression by human 
blood B cells following different preparation techniques. Single subject. Events 
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Figure 3.8. Quantification by ELISA of soluble human CD25 following 
stimulation. Each well contained 5x105 negatively isolated B cells and was 
stimulated for 60 hours. Error bars represent standard error of the mean (SEM). 
Single human spleen. Experiment conducted twice with similar results.  
 
These experiments, although not the main focus of investigation, open up a wide variety of 
questions. For example, it remains unclear whether surface CD25 is being cleaved and 
released or whether a splice-variant of CD25 which is soluble and does not contain the 
transmembrane portion of the protein is being released.  Moreover, it raises the question of 
what the biological relevance of B cell-released soluble CD25 might be. Could the molecule 
be neutralising IL-2? For example, in a recent paper by Li et al, it was shown that IL-2 from T 
cells can be ‘quenched’ by soluble CD25 from dendritic cells within the germinal centre (Li, et 
al. 2016). The original purpose of these experiments was simply to assess the methodological 
rigour of our experimental techniques and not to assess the biological relevance of this 
phenomenon. Therefore, at least for the time being, we have not looked at these questions, 
but they may be topics for further research in the future.  
 
3.1.3 IL-2 and its effect on B cell cytokine production 
We next asked how IL-2 would impact B cell cytokine production following activation in vitro. 
Stimulation of human splenic B cells with IL-2 alone did not induce IL-10 (Figure 3.9), IL-6 or 
TNFɑ, (data not shown) but addition of even very low quantities of IL-2 to CpG- or CD40L-
stimulated B cells led to a 6-fold augmentation of IL10 production (figure 3.9). We confirmed 






Figure 3.9. Quantification of IL-10 in culture supernatants from negatively 
isolated human splenic B cells stimulated with IL-2 and/or CpG and/or CD40L. 
Each well contained 5x105 negatively isolated B cells and was stimulated for 60 
hours. Significance calculated using a non-paired parametric two-tailed T-test. 
Error bars represent standard error of the mean. Single human spleen. 
Experiment conducted three times on different donated human spleen B cells 






Figure 3.10: Representative flow plots of IL-10 and TNF expression following 
IL-2 and CpG stimulation followed by co-culture with brefeldin, ionomycin and 
PMA (a standard protocol for staining for IL-10). These B cells were negatively 
selected from a single human spleen sample using a magnetic selection kit. 
Cells were gated on single, viable CD19 positive B cells. This experiment was 
conducted twice with an independent human spleen sample with similar 
results. 
 
In contrast, IL-6 and TNFα production was not affected by IL-2 (Figure 3.12 and 3.13) 
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 Figures 3.12 (left) and 3.13 (right). Quantification of IL-6 and TNFα in culture 
supernatant from human splenic B cells stimulated with IL-2 and CpG. Each 
well contained 5x105 negatively isolated B cells and was stimulated for 60 
hours. Error bars represent standard error of the mean (SEM). Single human 
spleen. Representative of three experimental repeats. 
 
Similarly, in murine splenic B cells, the addition of IL-2 enhanced IL-10 production by CpG 
stimulated B cells (Figure 3.14), confirming its capacity to augment IL-10-production by B cells 
in vitro.  
 
 Figure 3.14. Quantification of IL-10 in culture supernatants from murine splenic 
B cells stimulated with IL-2+/- CpG or CD40L. Each well contained 5x105 
negatively isolated B cells and was stimulated for 60 hours. Significance 
calculated using a non-paired parametric two-tailed T-test. Single murine 
spleen. Error bars represent standard error of the mean. Representative of 





To assess whether IL-2-mediated augmentation of IL-10-producing B cells would 
enhance their regulatory capacity, we activated human B cells in vitro in the presence or 
absence of IL-2, and subsequently co-cultured them with stimulated CD4 T cells. IL-2-treated 
B cells suppressed CD4+ T cell TNFɑ production (Figure 3.15), suggesting that IL-2 promotes 
the development of IL-10 producing B cells with the functional capacity to regulate CD4+ T 
cells.   
 
 Figure 3.15. Proportion of TNFɑ positive human CD4 T cells, as evidenced by 
intracellular cytokine staining, following co-culture with activated B cells 
generated in the presence or absence of IL-2.  Gated on single, viable, CD4 
positive events. Graphs show mean and standard error of the mean (SEM) of 
duplicates. of duplicates. Single human spleen. Significance calculated using a 
non-paired parametric two-tailed T-test. Representative of three experimental 
repeats.   
 
 
3.1.4 Pathways activated by IL-2 in B cells  
IL-2 receptor ligation activates three signalling pathways: i) the PI3K/Akt pathway ii) the 
JAK3/STAT5 pathway and iii) the MEK/ERK pathway. It has been suggested that in some 
subsets of regulatory B cells, IL-10 production requires Akt activation (Matsushita, Le Huu, et 
al. 2016). To examine the relative contribution of these pathways in IL-2-induced IL-10 
production in B cells, we used inhibitors of PI3K and MEK during stimulation of B cells and 




inhibitor wortmannin caused progressively reduced levels of IL-10. However, increasing levels 
of the MEK inhibitor U0126 had no or little impact on the cytokine’s production.  
 
Figure 3.16 (left) B cells stimulated as indicated in the presence of wortmannin, 
a PI3k inhibitor. Figure 3.17 (right) B cells stimulated in the presence of U-126, 
a MEK inhibitor. Stimulations in both cases were for 60 hours.  Graphs show 
mean and standard error of the mean (SEM) of duplicates of cells isolated from 
a single murine spleen. Data representative of two experiments. 
 
We also examined phospho-Akt, phospho-STAT-5 and phospho-ERK levels by intracellular 
flow cytometry. Initial studies suggested that stimulation with just 10 iu/ml of IL-2 induced an 
immediate increase in phosphorylated ERK levels followed by normalisation within a few 
minutes (figure 3.18). It is assumed that even with near-instantaneous fixation of tissue, 
signalling took place rapidly enough that the ERK is already phosphorylated in the time 0 
sample. In contrast, Akt phosphorylation slowly increased but was sustained over the 









Figure 3.18, 3.19, 3.20 Quantification of phosphorylation of ERK (top), STAT5 
(middle) and Akt (bottom) over time following IL-2 stimulation. NB: The data 
point correlating to ‘Time 0’ reflects samples which were IL-2-stimulated and 
then immediately fixed.  
 
There are couple of potential weaknesses in this set of experiments which are worth 
noting. First, it is not clear whether the reduction in IL-10 production following 
concomitant inhibition of AKT through wortmannin actually inhibited the production of 
IL-10, reduced the proliferation of B cells, or even caused cell death of B cells. To 
understand this better, a viability stain and cell count after the stimulation would seem 
appropriate. Moreover, wortmannin is known to have some off target effects (Bain, et 
al. 2007) and other more specific inhibitors may be more appropriate for further testing 





3.1.5 In vivo effect in mice  
We developed an in vivo murine model to look at the effects of IL-2 on antibody production. 
40 million splenocytes were transferred from a BALB/c mouse into a C57BL/6 mouse 
intravenously to induce B cell activation and donor-reactive antibody production. In the 
treatment group, mice were simultaneously given IL-2 daily. This is similar to a model 
described by Cravedi and colleagues (Cravedi, Lessman and Heeger 2013). We hypothesized 
that mice given IL-2 would have a greater number of IL-10 producing regulatory B cells. We 
observed a greater number of CD21high, CD23 high B cells (figures 3.21 and 3.22). This 
population was enriched in CD9 positive B cells, which have been recently shown to provide a 
useful marker of regulatory B cells (figure 3.21, far right plot) (J. Sun, et al. 2015). We have 
not been able to analyse IL-10 production due to problems with intracellular staining. This 




Figure 3.21 (top). Representative flow cytometry plot showing increased 
numbers of CD21+CD23+ transitional B cells following allogeneic splenic 
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transfer and IL-2 treatment. Far right flow cytometry plot previously gated on 
single viable CD19 positive CD9 high events. Figures 3.22 and 3.23 (bottom left 
and right). Quantification of CD21+CD23+ transitional B cells. N=9 in total (2-4 
per group). Significance calculated using a non-paired parametric two-tailed T-
test. Experiment performed twice with similar results.  
 
A number of aspects of the experiments discussed in this section need development. 
However, before considering these questions it is worth asking whether, given that there are 
now strong data in the following section suggesting increases in the number of regulatory B 
cells in humans following low-dose IL-2 treatment, the need to develop this murine 
experiment may have lessened somewhat. After all, the vast majority of murine experiments 
in medical science serve as a surrogate to understand human physiology and pharmacology. 
This reason is in part why this experiment has not been further developed.  
If, however, this experiment were to be developed, one of the key questions that still 
needs to be asked is, while we know that the CD21 high CD23 high population are enriched in 
CD9 cells, are these cells truly IL-10 producing cells?  
 
3.1.6 In vivo effect in humans 
To determine the relevance of these observations to the generation of B-regs in humans in 
vivo, we analysed peripheral blood mononuclear cells from patients enrolled in the Adaptive 
Study of IL2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency) study 
(Truman, et al. 2015). Participants enrolled in this low-dose IL-2 trial were aged between 18 
and 70 years and had been diagnosed with type I diabetes within 60 months of enrolment.  
Patient were given a dose (0.09 to 0.47 x 106 international units (IU) per m2) of the 
recombinant IL-2 (rIL-2) aldesleukin every two to five days. To put these doses into context, a 
typical dose used for high dose IL-2 for the treatment of renal cell carcinoma or malignant 
melanoma is in the order of 720,000 iu/kg three times per day for up to 15 doses. In a 75kg 
individual, this equates to 162x106 IU per day. In contrast low-dose therapy is about 0.172 
x106 units per day for average patient with a surface area of 1.8m2. Therefore, the low dose 




We chose to analyse samples taken from subjects given the lowest aldesleukin dose 
of 0.09 x 106 IU/m2 as a control as this had no effect on T cells, and from subjects given the 
higher but still generally low-dose ranges of 0.2-0.47 x 106 IU/m2 (Figure 3.24).  See above 
reference for full details of the study.  
 
 
 Figure 3.24 Diagrammatic schema summarizing the two treatment arms of the 
rIL-2 study. Patients with recently diagnosed type 1 diabetes mellitus received 
negligible dose (0.09x106 IU/m2) or low dose (0.2-0.47x106 IU/m2) aldesleukin 
every two to five days.  
 
Overall, there was no change in peripheral B cell counts between samples taken prior to rIL-2 
administration and those taken at visit 10 (after 8 doses), 20-50 days after commencing 




diagnosed with  

























 rIL2  







Figure 3.25 (left) Total peripheral blood B cell numbers remain unchanged 
during rIL2 treatment B cell count taken during visits 2, 4, 6, 8 and 10 of 
DILfrequency trial of patient given 0.09x106 IU/m2 aldesleukin. Figure 3.26 
(right) Total peripheral blood B cell numbers in patients given 0.2-0.47x106 
IU/m2 aldesleukin. Red line indicates mean B cell number. There was no 
significant difference at any time point in comparison to the original timepoint. 
Significance calculated using a paired parametric two-tailed T-test. 
 
However, in participants who received 0.2-0.47 x 106 IU/m2 rIL-2 we observed a significant 
increase in the number and proportion of IL-10 producing B cells in contrast to those 









Figures 3.27 and 3.28 (top left and right respectively). Proportion or absolute 
number of IL-10-positive B cells in patients prior to and following the 
administration of 0.09x106 IU/m2 aldesleukin. Figures 3.29 and 3.30 (bottom 
left and right respectively). Proportion or absolute number of IL-10-positive B 









Figure 3.31 (top) Representative flow cytometry plot of IL-10 expressing B cells 
pre- and post-administration of 0.09x106 IU/m2 aldesleukin. Figure 3.32 
(bottom). Representative flow cytometry plot pre- and post 0.2-0.47x106 IU/m2 
aldesleukin.  
 
A number of methodological and practical considerations are worth mentioning at this point. 
Without doubt, a prospective double blinded study would be an ideal methodological 
framework within which to assess in vivo the effects of IL-2 in B cells. However, in a doctoral 
program which from the outset was not based around a clinical trial, such an undertaking 
would not be practically possible because of both time and financial commitments required. 
In addition, although the nine participants were able to generate statistical significance, a 
greater number of patients in the study would be useful in future studies. Finally, while we 
are aware that the 0.09 x 106 IU/m2 dose does not have significant effect on T cells and 
therefore assumed likewise of B cells, a better control population may be use either no IL-2 























































IL-10-producing B cells following low-dose IL-2 administration, these methodological 
shortcomings show the need for a future study tailored to studying B cells specifically.  
 
3.2 Discussion 
In summary, the activation of human peripheral blood and splenic B cells in the presence of 
IL-2 promotes B cell production of the immunoregulatory cytokine IL-10, augmenting 
functional CD4 T cell suppression in vitro. This appears to be mediated via a PI3k pathway in 
agreement with earlier experiments. In vivo, the administration of low-dose IL-2 to murine 
and human subjects increased the number of circulating IL-10-producing B cells, with 
therapeutic potential to modulate deleterious immune responses. 
Though B cells may not necessarily encounter both IL-2 and CpG in vivo, as discussed 
earlier, CpG was used as surrogate stimulus in our experiments for TLR ligation and such 
stimulation may occur in autoimmune conditions where self-nucleic acid is present. In 
secondary lymphoid organs, adjacent T cells may potentially act as a source of IL2.  Therefore, 
given the proximity of T cells and B cells in secondary lymphoid tissues, it would not be 
surprising if B cells came in contact with IL-2 in vivo in a paracrine fashion along with TLR 
stimulation. 
 
3.3 Future plans 
Many questions remain unanswered and experiments are currently being devised to address 
these:  
1. In a number of disease processes such as systemic lupus erythematosus, it is possible 
to induce disease remission through the use of IL-2. However, it remains unclear 
whether this is wholly T-reg-mediated or partially – or even wholly – B-reg mediated 
given the pluripotent effects of IL-2.  
2. How long can B-regs be maintained? For example, what is the maximum effective 
period between doses? Does the efficacy of IL-2 drop after multiple doses?  What is 
the washout period of IL-2?  




4. What is the effect on other types of leucocytes? With the advent of single-cell RNAseq, 
it may become easier to answer these questions.  
5. Given the effects IL-2 has on T follicular helper cells, will immunisation against 
antigens become less effective in these patients (Ballesteros-Tato, et al. 2012)?  
6. Can IL-2 treatment be given to patients with solid-organ transplants? Already, we are 
aware of one study at Guy’s and St Thomas’ Hospital, London in which liver transplant 
recipients are receiving rIL-2 treatment. Can this be expanded to kidney, pancreas and 
multi-visceral organ transplant recipients? It is our hope that such a trial may be 
possible soon.  
7. Are there other off-the-shelf drugs which might improve outcomes? A screening of 














The experiments described in the previous two chapters explore two sides of B cell 
behaviour independent of their capacity as antibody producers: In the first half of the thesis, I 
have explored the more pro-inflammatory aspects of B cell behaviour in the context of acute 
kidney injury (figure 4.1). In the early stages of AKI, CD11b+CD19+B220- B cells become 
prominent in the blood and these lymphocytes employ the MAC-1 complex to migrate into 
damaged renal tissue. Upon exiting the vasculature and entering the renal interstitium, B 
cells release CCL7 which attract a wide range of inflammatory myeloid cells. By blocking CCL7 
it is possible to ameliorate disease. Conversely, deficiency of Siglec-g, an inhibitory protein 
found predominantly on B cells, leads to an excess of B cell activity and B1 cell numbers, and 
worsens the severity of AKI. A Siglec-g agonist, sialic acid, ameliorates AKI. Analysis of human 






Figure 4.1: Schematic drawing of the behaviour of B cells during AKI.  
 
In the second half of this thesis, I looked at how B cells are able to regulate 
inflammation. Specifically, I looked how such B cells might be induced in vivo. Following 
activation, B cells upregulate expression of CD25, a key component of the IL-2 receptor, and 
thus make themselves receptive to IL-2 signalling. The IL-2 signal is crucial in turning B cells 
from an inflammatory phenotype, defined by the production of IL-6 and TNFα, to a regulatory 
one defined more by IL-10. In vivo, the administration of low-dose IL-2 to both mice and 
human subjects increased circulating levels of IL-10-producing B cells, suggesting this may be 
a method of inducing regulatory B cells.  
 
 
Figure 4.2: Schematic drawing of behaviour of stimulated B cells following IL-2 
exposure.  
 
A number questions – and perhaps potential conflicts – arise from these two sections 
and are discussed in this conclusion: 
1. The most obvious question which brings together both of these chapters, is 
how it is possible to reconcile these almost diametrically opposing functions 
of proinflammatory B cells in AKI  on the one hand and anti-inflammatory B 




of whether the same B cell can have the dual pro-inflammatory and anti-
inflammatory roles, and if so, is the B cell’s functional remit temporally and 
environmentally dictated? For example, in AKI, are infiltrating B cells initially 
pro-inflammatory but later anti-inflammatory during the resolution phase? 
Or are these dual roles of B cells the result of distinct B cell populations, one 
pro-inflammatory and the other anti-inflammatory?  
2. How do CD11b-expressing and CCL7-producing B cells fit into our current 
understanding of inflammatory B cells?  
3. How does the role of IL-2 fit into our current understanding of regulatory B 
cells?  
4.1 The duality of B cells 
Our experiments show that B cells can have both pro- and anti- inflammatory effects.  Such 
dual functionality is a phenomenon observed in many immune cell subsets; for example, 
there are CD4 and CD8 T cells with both effector and regulatory functions (Dias, et al. 2017).  
In the germinal centre, there are T follicular helper cells and T follicular regulatory cells 
(Linterman, et al. 2011). Similarly in innate immunity, macrophages may produce pro-
inflammatory cytokines and chemokines, but in other contexts produce negative regulatory 
cytokines including IL-10 (Cohen and Mosser 2013).   
Our data show that B cells may also have diverse functions in immunity beyond 
antibody production. In the context of AKI, B cells produce the monocyte-recruiting 
chemokine CCL7, promoting inflammation.  This is consistent with previous descriptions of B 
cell function following myocardial infarction (Zouggari, et al. 2013).  
We also show that B cells can produce the regulatory cytokine IL-10, and this is 
augmented by exogenous IL-2.  This raises the possibility that the current use of low dose IL-2 
clinically might induce B cells with a regulatory function.  This may also be relevant to AKI. 
Our experiments addressed the role of B cells at early time points, but over time there may 
be transformation towards a more regulatory B cell phenotype. This concept is supported by 
data showing that during dehydration and AKI, IL-2 levels within the kidney rise (Goes, et al. 
1995) (Sugama, et al. 2013). More recently, there has been a suggestion that administration 




AKI by their effects on regulatory T cells (Kim, et al. 2013). However this effect could be 
mediated via effects on B cells rather than T cells alone. Such observations provide the 
impetus for future experiments.  
 
4.2 CD11b-expressing and CCL7-producing B cells and how these ideas may fit into the 
current literature 
The notion of CD11b-expressing B cells, while controversial, has not been without a body of 
literature as previously discussed. Most recently, Liu and colleagues have described CD11b 
positive B cells in the liver having an immunoregulatory effect on CD4 T cells in a murine 
experimental model of autoimmune hepatitis (Liu, et al. 2015). Moreover, there is extensive 
literature on how myeloid cells take advantage of CD11b and CD18 to enter endothelium. 
Thus, it is not particularly surprising that CD11b might be the mechanism by which B cells 
enter renal tissue.  
 Broadly speaking, one of the main questions that remains unanswered is whether 
CD11b expression on B cells regulate the severity of AKI. To answer this, two potential 
approaches are possible. One is to give either CD11b wildtype or knockout B cells to a B cell 
deficient mouse such as a µMt mouse, then give a renal insult and analyse the outcome by 
serum and tissue analysis (figure 4.3). Alternatively, another method may be to generate a 
tissue-specific knockout through a flox-cre construct. A CD11bflox/flox CD19-cre mouse would 
be generated such that there would be reduced or no expression of CD11b on B cells while 
other cell lines would express CD11b as normal. Subsequently, again, these mice, along with 
their appropriate controls, would undergo folic acid-induced AKI and a comparison of the two 






Figure 4.3: Schematic of a proposed model of exploring the role of CD11b on B 
cells in regulating the severity of AKI 
 
 
Figure 4.4: An alternative schematic proposed model of exploring how 
important CD11b on B cells may be for regulating the severity of AKI.  
 
Other questions include, is CD11b newly expressed following the renal insult? If so, 
what are the signals that drive this expression on B cells? Is the expression of CD11b 
transient? If so, does the lack of expression of CD11b cause B cells to leave the kidney? Or is 
CD11b expression present even before the insult? If so, is the source of these B cells 
exclusively from the spleen or could there be mobilisation of B cells from sources such as the 
peritoneal cavity where there are known to be far greater numbers of CD11b positive B cells, 
albeit with overall smaller total numbers of B cells? As with all other questions raised in this 
chapter, future experiments will need to address these points.  
 The expression of CCL7 by B cells is broadly in concordance with a recent publication 
by Zouggarri and colleagues who reported this phenomenon in the context of myocardial 
infarction, another form of sterile inflammation (Zouggari, et al. 2013). As with CD11b, the 
main questions that remain relate to what drives the expression of this protein. For example, 
while I have shown earlier how B cells have the potential to produce this cytokine following 
TLR and BCR stimulation in vitro, what are the stimuli that may induce its expression in vivo?  
 Thus, whilst the roles of CD11b for extravasation and CCL7 expression by B cells have 
not previously been described in AKI, hints that this may be important arise from other 






4.3 IL-2-induced B cells and how these ideas may fit into the current literature 
It has been known for some time that B cells may have the potential to respond to IL-2. The 
work of Korsmeyer et al and Muraguchi et al demonstrated that the IL-2 receptor was 
present on B cells (Korsmeyer, et al. 1983) (Muraguchi, et al. 1985). In addition, at about the 
same time, there was a suggestion that IL-2 may stimulate B cell proliferation (Mingari, et al. 
1984) (Gearing, et al. 1985). However, there has been little consideration of how IL-2 might 
impact the function of B cells.  Our work demonstrates that IL-2 promotes IL-10 production, 
adding to the cytokines known to augment IL-10 production in B cells, with BAFF being one of 
the most important to date (Yang, et al. 2010). 
As noted previously, regulatory B cells are not a distinct subset identified by the 
expression of one specific transcription factor or marker. Rather, a number of B cell subsets 
have the capacity to produce IL-10, for example, B1 cells and transitional B cells. Therefore, 
which subset of B cells are most enriched with CD25 positive cells? And which subset is most 
responsive to IL-2? In terms of the capacity of these subsets to respond to IL-2, we have not 
determined the proportion of each subset that expresses CD25 at rest or after stimulation; 
rather we have measured this in total B cells.  Complicating this question is that in humans, 
the markers identifying B1 cells are contentious and the population is not discrete, as 
discussed in the introduction. Given this limitation, it is not clear if one could address 
whether human B1 cells are enriched in CD25 positive cells. Investigating the upregulation of 
CD25 in B cell subsets post-stimulation would require subset sorting prior to stimulation, due 
to the changes in surface markers that occur with stimulation. The limited number of samples 
available from the clinical trial precluded such an approach in the current study. 
Perhaps most importantly, what requires further inquiry is whether these IL-2 induced 
B cells are clinically relevant for ameliorating autoimmunity or inducing transplant tolerance. 
Strictly speaking, the clinical trial has seen an augmentation of the IL-10 population but 
further work is necessary to ascertain whether this population is having an effect on disease. 
On one end of the spectrum of relevance, IL-2 stimulated B cells may have no effect at all on 
autoimmune diseases or transplantation, though this is unlikely. At the other extreme, IL-2 
stimulated B cells may be sufficient – independent of the aid of IL-2 induced regulatory T cells 




Chapter 5: Methods 
All temperatures are in Celsius.  
5.1 Washing of cells 
1. Unless otherwise stated washing of cells involved filling the container with 2 to 3 
millilitres of ice-cold PBS. 
2. The container was centrifuged at 1300 RPM for 5 minutes at 4 degrees without a lid.  
3. The excess fluid was tipped out. 
4. The container was ‘racked’ on a rough surface such as the top of a tube rack to 





5.2 Enzyme-linked immunosorbent assay 
1. In the interests of expenditure, most ELISA assays were carried out with a number of 
changes from the manufacturer’s instructions. Most of the ELISAs done in this thesis 
were purchased from R&D  
2. 50ul of capture antibody was used to coat the bottom of an ELISA plate and stored 
overnight in the dark at 4 degrees with a lid. 
3. The capture antibody was ‘flicked off’ into a sink. 
4. To wash, the whole plate was submerged in PBS with tween and then the fluid was 
again flicked off. This was repeated three times. The plate was subsequently 
submerged in PBS alone and the fluid was flicked off. This was also repeated three 
times.  
The plate was patted dry at the end of washing.  
5. 100ul of blocking solution was added to each well and stored with 1 hour at room 
temperature. 
6. The plate was washed as above.  
7. 50ul of antigen-containing solution was added to each well and stored for minimum 2 
hours at room temperature or overnight at 4 degrees.  
8. Plates were washed as above.  
9. 50ul of detection antibody was added to each well and stored for 2 hours at room 
temperature. 
10. Plates were washed as above.  
11. 50ul of streptavidin horseradish peroxidase was added to each well and stored for 20 
minutes at room temperature. 
12. Plates were washed as above.  
13. 50ul of 3,3',5,5'-Tetramethylbenzidine substrate solution was added to each well and 
stored for 20 minutes at room temperature. 
14. 25ul of sulfuric acid stop solution was added to each well. 










5.3 Preparation of tissue for confocal microscopy 
1. Portions of splenic tissue were cut into sections approximately 8 millimeters long. 
2. The tissue was fixed in 1% paraformaldehyde for 24 hours followed by 30% sucrose 
solution for a further 24 hours 
3. Tissues were set in OCT moulds and frozen down to minus 80 degrees 
4. 25 micrometer sections of tissues were cut at -25 degrees using a cryostat and placed on 
poly-L-lysine slides.  
5. A border was drawn around the tissue section using a wax pen.  
6. Sections were air-dried for approximately 15 minutes and subsequently frozen to -20 
degrees until the tissue was ready for staining. 
7. Sections were defrosted and rehydrated using PBS for 15 minutes 
8. PBS was aspirated off and tissue was blocked for non-specific staining using 1% murine 
serum and 1% Fc block in PBS for 1 hour at room temperature 
9. Above blocking solution was aspirated off and 75 ul of antibody solutions were added to 
each sample. Antibody solution was made up in either PBS or permeabilisation solution 
depending on whether intracellular stains were included.  
10. Samples were incubated for 24 hours at 4 degrees in a damp chamber to prevent 
evaporation of antibody solution. 
11. Slides were washed in PBS with 1% tween for 15 minutes three times, while ensuring 
that excess light was not applied to the slides. 
12. The slides were dried as much as possible without disrupting the tissue. 
13. A cover slip was applied with 15 microlitres of mounting solution per tissue sample. 
14. The slides were dried at room temperature with ambient humidity. 






5.4 Genome-wide RNA analysis  





5.5 Human peripheral blood B cell CD25 and CD122 expression following stimulation 
1. Following ethical approval, discarded human leucocyte cones from healthy blood 
donors were obtained from the National Health Service Blood and Transplant, 
Cambridge.  
2. Until the cells were fixed, all of the following steps were carried out in a Category II 
biosafety cabinet.  
3. Histopaque was brought out of the refrigerator to warm up to room temperature. 
4. Leucocytes were diluted in ice-cold running buffer (produced in-house: 0.5% bovine 
serum albumin (Sigma-Aldrich), 0.4% 0.5M pH 8.0 ethylenediaminetetraacetic acid in 
sterile phosphate buffered solution) and isolated using a Histopaque-1077 (Sigma) 
density gradient.  
5. Cells were washed twice at 4 degrees and resuspended in ice-cold Roswell Park 
Memorial Institute Solution 1640 (RPMI) supplemented with 10% fetal calf serum, 1% 
penicillin and streptomycin (all Sigma) in concentrations no greater than 106 cells per 
200 μl of supernatant. Cell counting was carried out manually using a 
haemocytometer.  
6. Cells were stimulated overnight with CpG ODN 2395 (5ug/ml, InvivoGen) and/or CD40 
ligand (1ug/ml, Peprotech).  
7. Cells were washed with ice-chilled PBS and blocked for non-specific staining using 1% 
normal rat serum (ThermoFisher) and 1% human FcR block (Miltenyi Biotec) for 30 
minutes. 
8. Without rewashing, cells were stained with primary surface antibodies for 30 minutes 
at room temperature.  
9. Cells were washed at room temperature and viability stain was applied for 15 minutes 
at room temperature. Details of all human antibodies and staining buffers used are 
listed below. Two antibodies were used for both CD25 and CD122.  
10. Cells were washed and preserved in fixation fluid (produced in-house). 
11. Prepared samples were analysed using a BD LSRFortessa flow cytometer.  





Antigen Clone Chromophore Manufacturer Catalogue 
number 
CD19 HIB19 BV650 BioLegend 302238 





MOPC-21 APC BD Pharmingen 555751 
CD25 2a3 APC BD Bioscience 340907 





MOPC-21 PE BioLegend 400112 





MOPC-21 PE BD Pharmingen 554680 






5.6 Human spleen B cell CD25 and CD122 expression  
1. Following ethical approval, human spleen was retrieved from cadaveric organ 
transplant donors whose organs were turned down for transplantation.  
2. Until the cells were fixed, all of the following steps were carried out in a Category II 
biosafety cabinet.  
3. Histopaque was brought out of the refrigerator to warm up to room temperature.  
4. Splenic tissue typically about 1 centimeter diameter was cut into small pieces using 
conventional surgical scissors.  
5. The tissue was mechanically pushed through a 100 micron metal filter using the 
plunger of a 2.5 ml syringe with approximately 50ml of ice-cold cRPMI.  
6. The above step was repeated.  
7. The cell suspension was centrifuged through a histopaque gradient at room 
temperature for 25 minutes at 2300 RPM with the gentlest acceleration and 
deceleration settings.  
8. Cells were carefully removed from the leucocyte strata using a disposable stripette.  
9. Cells were washed twice in ice-cold cRPMI at 4 degrees Celsius at 2500 RPM for 10 
minutes per cycle.  
10. For experiments involving cell surface expression of the IL2 receptor, cells were 





5.7 Human spleen B cell IL-10 production 
1. Cell suspension was generated from whole spleen as described above.  
2. The splenocytes were resuspended in running buffer.  
3. B cells were magnetically negatively isolated as per the manufacturer’s instruction.  
4. B cells were placed in a round-bottomed, 96 well plate in 200ul of supernatant at 
5x105 cells per well.  
5. Cells were stimulated with a combination of CD40 ligand, CpG, or rIL2 (aldesleukin) 
for 60 hours.  





5.8 Human spleen B cell co-culture 
1. For co-culture experiments, B cells and CD4 T cells were negatively isolated (Miltenyi) 
as per the manufacturer’s instructions.  
2. B cells were stimulated overnight with CpG, IL-2 or a combination of ligands. 
3. Simultaneously, T cells were stimulated overnight on an anti-CD3 antibody (OKT3, 
Abcam)-coated 96-well flat-bottomed plate.  
4. Cells were subsequently washed three times to eliminate any residual IL-2 (estimated 
dilution: 2.7x104-fold).  
5. Cells were co-cultured overnight at a ratio of 1:5 B cells to CD4 T cells.  
6. For the last five hours of co-culture, cells were exposed to PMA (Sigma), ionomycin 
(Sigma) and brefeldin A (Biolegend).  
7. Cells were stained, fixed, permeabilised and intracellularly stained as per human 





5.9 Human protein phosphorylation staining  
 Cells from recent phlebotomy: 
1. If leucocytes were derived from fresh blood, 300 ul of citrate was poured in a 50ml 
conical centrifuge tube.   
2. Approximately 3 milliliters of blood was drawn from a healthy member of the 
laboratory.   
3. Blood was immediately emptied into the tube containing citrate.  
4. Blood was gently swivelled but not aggressively shaken as this was likely to blood stain 
the bottle cap unnecessarily  
5. 200 ul of blood was aliquoted into FACS tubes. 
6. Cells were treated with 1 ml of red cell lysis buffer for 10 minutes or until fluid 
changed to a paler colour. 
7. Cells were washed with cRPMI 8. Excess fluid was tipped off.  
8. Cells were stimulated overnight with 5ug/ml of CpG to upregulate IL-2 receptor 
expression.  
 Cells from leucocyte cones: 
9. Cone leucocytes were prepared in the manner described above. 
10. Cells were aliquoted into 96 well-round-bottomed plates with no more than 4 million 
cells per well.  
11. Initially cells were suspended in 200 microlitres of cRPMI. 
12. Stimulus such as CpG was suspended in a further 50 microlitres of cRPMI. 
13. Initial stimulation was usually 24 hours.   
 After above steps, all samples were stained as follows:  
14. Samples were centrifuged and supernatant pipetted off.  
15. Primary surface antibodies compatible with permeabilisation kits were applied. Block 
for preventing non-specific staining was not done in the interests of processing tissue 
as quickly as possible.  
16. Samples were transferred to FACS tubes if not already done previously.   
17. Fixation solution was warmed to 36 degrees Celsius.  




19. Samples were fixed with equal amount as the sample supernatant.  
20. Samples were incubated at 36 degrees for ten minutes  
21. Permeabilisation solution was chilled on dry ice. 
22. 1 ml of permeabilisation solution was applied to each sample while being vortexed to 
ensure sample did not freeze and solidify.  
23. This procedure was done in the hood to ensure minimal inhalation of methanol. 
24. Samples were left to permeabilise at room temperature for 20 minutes. 
25. Samples were centrifuged and excess fluid pipetted off. 
26. Samples were stained with relevant phosphorylation antibody. 
27. After 1 hour of staining at room temperature, a further 1 ml of distilled water was 




5.10 rIL2-treated human blood leucocytes intracellular staining 
1. Details of the methods of the DILFrequency trial have been described at length 
elsewhere. In brief, the trial was a mechanistic, non-randomised, repeat dose, open-
label, response-adaptive study of 36 participants with type I diabetes mellitus using 
varying doses and frequencies of low-dose rIL-2 intended to augment Treg 
populations. In our study, we chose a look at a selection of patients from the study 
with rIL2 doses varying between 0.09 x 106 iu/m2 to 0.47 x 106 iu/m2 administered 
every 2 to 5 days. These doses reflect the full range of doses given. Analysed blood 
samples were taken before rIL2 treatment (visit 2) and at the beginning of every other 
visit thereafter (visits 4, 6, 8 and 10). Administration of the original clinical trial was 
conducted by Prof John Todd and Dr Frank Waldron-Lynch, along with members of 
their scientific and medical team. Samples were retrieved from liquid nitrogen 
preservation by Ms Jane Kennet, research nurse.  
2. Retrieved leucocyte samples were defrosted in a water bath at 36 degrees Celsius for 
one minute.   
3. Cells were immediately transferred to 15 millilitres conical centrifuge tubes filled with 
ice-cold cRPMI. 
4. Cells were washed twice.  
5. Cells were rested for 24 hours at a concentration of approximately 8x105 cells per 200 
μl well. All resting and subsequent stimulation of cells took place in a 96-well round-
bottomed plate in an incubator at 36ºC and 5% CO2.  
6. Cells were stimulated with CpG ODN 2395 (10ug/ml) for 48 hours.  
7. During the last 5 hours of this stimulation, cells were additionally exposed to phorbol 
myristate acetate, ionomycin, and brefeldin. 
8. Prior to primary antibody staining, cells were blocked for non-specific binding with 
normal rat serum and FcR block as described above.  
9. Extracellullar antibodies were as described above.  
10. Cells were fixed and stored overnight at 4ºC and permeabilised the following day 
using an cytosolic intracellular staining kit as per the manufacturer’s instructions in 




11. Intracellular stains were applied for 1 hour at room temperature in darkened 
conditions.  
12. Cells were washed. 
13. Cells were analysed immediately on a flow cytometer.  
14. All samples were processed in duplicate along with an unstimulated isotype control. 
Stained leucocytes were analysed on a BD LSRFortessa flow cytometer.  
15. Flow cytometry files were analysed on FlowJo Version 10 software.  
 
 Clone Chromophore Manufacturer 
CD19 HIB19 BV650 BioLegend 
IL-10 JES3-9D7 PE BioLegend 
TNFα MAb11 APC BioLegend 






5.11 Murine splenic cell preparation for as cell suspension 
1. Mice were euthanized with a rising concentration of CO2. Murine spleen was dissected 
using a sterile technique immediately following confirmation of death. The spleen was 
suspended in sterile PBS in a 15 ml conical centrifuge tube and transported on ice from 
the animal facilities to the laboratory. 
2. cRPMI and MACS running buffer were placed on ice. The centrifuge was pre-cooled to a 
temperature of 4 degrees Celsius.  
3. All tissue preparation was subsequently done in a sterile biosafety cabinet using sterile 
techniques. As much as possible, cells were kept on ice.  
4. Fat was dissected from the spleen and disposed. 
5. The spleen was compacted and pushed through a 40 micrometer disposable sieve along 
with 4 millilitres of cold cRPMI using the rubber end of a plunger from a 1 ml syringe. 
6. The cell suspension was passed through a new 40 um sieve again to reduce fat content.  
7. Splenocytes were resuspended in 50ml of cRPMI in a 50 ml conical centrifuge tube.  
8. Cells were centrifuged at 1300 RPM for 5 minutes at 4 degrees. 
9. Excess fluid tipped off and 1 ml of red cell lysis was added to the cells for 1-2 minutes or 
until the colour of the suspension turned from a bright red to a colour similar to cRPMI.  
10. Cells were resuspended again in 50 mls of cRPMI and centrifuged at 1300 RPM for 5 
minutes at 4 degrees. 
11. Excess fluid was tipped out and cells counted using a haemocytometer. Cells were ready 






5.12 Murine spleen B cell CD25 expression 
1. Mouse spleens were collected from 6-12 week-old BL/6 wildtype mice bred within the 
University of Cambridge mouse facilities and processed as described above.  
2. Methods for en masse stimulation experiments and isolated B cell experiments were 
as per human splenic experiments except murine CD40L (1ug/ml, Peprotech) and LPS 
(10ug/ml, Sigma). 
 
 Clone Chromophore Manufacturer 
B220 RA3-6B2 APC/Cy7 Biolegend 
CD25 PC61 PerCP/Cy5.5 Biolegend 






5.13 Murine IL-2-treated B cell transfer  
1. B cells were isolated from a wildtype BL/6 mouse as previously described 
2. B cells were stimulated in 96-well round-bottomed plates. 
3. Cell concentration was 1 million B cells per 250ul well 
4. Cells were stimulated either with either CpG (5ug/ml) or IL-2 (100 iu/ml).  
Vehicle stimulated was cRPMI 
5. Purity was confirmed to be >95% 
6. Cells were stimulated in at 36 degrees and 5%CO2 for 48 hours 
7. Splenocytes were BALB/c mice were isolated as previously described. 
8. BL/6 B cells and BALB/c splenocytes were mixed to create a final concentration of 5 
million B cells and 14 million splenocytes per 200 ul injection. 
9. Mice were placed in a heater for at least 10 minutes before tail vein injection of B cell 
and allogeneic splenocytes.  
10. Daily weights of the mice were observed.  
11. Mice were culled on day 7. 





5.14 Alloantibody detection assay 
1. Serum collected from mice were co-cultured with splenocytes or thymocytes from 
allogeneic mouse for 10 minutes at multiple concentrations. 
2. Cell were washed. 
3. Cells were stained with primary antibodies and rat fluorescently labelled anti-mouse 
anti-IgG antibody 




5.15 Preparation of folic acid 
1. Folic acid was weighed within a 50 millilitre conical centrifuge tube.  
2. Sodium bicarbonate solution was added to the solution 
3. The tube was covered in aluminium foil.  
4. The solution was mixed in a shaker at 36 degrees overnight 
5. Each experiment was conducted using a single batch of FA.  
NB: How well the folic acid is dissolved in solution appears to have a significant 
bearing on its potency to induce AKI. In order to ensure minimal batch to batch 





5.16 Murine intravascular labelling of cells 
1. Appropriate approval from the animal facilities as well the Home Office was gained 
before commencing this experiment.  
2. Mice were placed in a warming chamber at 36 degrees for at least ten minutes.  
3. Mice were transferred to a mouse restrainer. 
4. Mice were injected pan-CD45 antibody via the tail vein 
5. The restrainer was released so that the mice could move within the restrainer tube 
for 2 minutes 
6. Mice were culled using rising carbon dioxide levels. 






5.17 Surgical renal pedicle clamping 
1. Appropriate approval from the animal facilities as well the Home Office was 
gained before commencing this experiment.  
2. Mice were anaesthetised using inhaled vaporised isofluorane. 
3. Mice were placed on a warmed surface throughout the operation. 
4. A midline laparotomy was undertaken and the bowels moved to expose the renal 
pedicles.  
5. Clamps were placed on the renal pedicle for 45 minutes.  
6. All surgical procedures were done by either Mr Kourosh Saeb-Parsy or Mr Jack 
Martin (Department of Surgery, University of Cambridge) using an operating 
microscope. 
7. Following the end of clamping, the mice were injected subcutaneously with 100 ul 
of PBS. 
8. Laparotomy was closed and the mice were observed while coming out of 
anaesthesia. 
9. Mice were inspected on the evening of the operation. 
10. Mice were culled and tissue analysed in the same manner as previously described 





5.18 Acute tubular necrosis scoring of haematoxylin and eosin stained kidney samples 
Scoring was conducted as previously described (Clatworthy, et al. 2012).  
1. Kidneys were H&E stained and prepared as described elsewhere.  
2. Ten random non-overlapping fields were photographed using a light microscope. 
3. A trainee nephrologist assessed the histology images in a blinded fashion on a 
personal computer.  
4. Scoring of tubulointerstitial damage involved three parameters: tubular necrosis, 
tubular dilatation, and cast formation. Scores were as follows: involvement of 0–25% 
of tubules within each cortical or medullary high-powered field (HPF), 1; 25–50%, 2; 
50–75%, 3; and 75–100%, 4. Therefore, minimum score was three.  





5.19 Competition assay of wildtype of CD11b-/- B cells during acute kidney injury 
1. Appropriate approval from the animal facilities as well the Home Office was gained 
before commencing this experiment.  
2. CD11b-/- mice were acquired from the Jackson Laboratory and transferred from the 
US. These mice were on a CD45.2+/+ background. 
3. CD11b-/- and CD45.1+/+ mice were culled in rising CO2 as per local standard operating 
practices. 
4. The spleen was removed in a sterile fashion and transported to the laboratory on ice 
in sterile PBS.  
5. B cells were negatively isolated as described elsewhere.  
6. B cells were counted and an equal number of each type of B cell was mixed.  
7. A small sample of the cells were kept to test for cellular purity on a flow cytometer.  
8. Cells were transferred to the mouse facilities on ice. 
9. Mice placed in a heating apparatus set to 36 degrees to attain vasodilation.  
10. Cells were injected into the mice in volumes no greater than 200ul. 
11. Mice were observed for 20 minutes following the injection to ensure there were no 
unexpected consequences. 
12. 24 hours later, mice were injected intraperitoneally with 300mg/kg folic acid.  
13. 16 hours later, mice underwent intravenous CD45 labelling and culling as described 
elsewhere.  





5.20 qPCR analysis of human renal tissue following acute kidney injury 
1. Following ethical approval, human kidney was retrieved from cadaveric organ 
transplant donors whose organs were turned down for transplantation. 
2. Sample preparation was undertaken by various members of the Clatworthy laboratory 
including Drs Miriam Berry, Kevin Loudoun, Rebeccah Mathews and Alexandra Riding.  
3. A section of kidney cortex typically measuring 8 x 8 x 8 mm was snap frozen in liquid 
nitrogen or in a -80 degree freezer.  
4. Samples were retrieved from the freezer were placed on a petri dish on top of dry ice.  
5. A small sample typically measuring approximately 2 to 3 millimeters was cut using a 
disposable razor blade.  
6. Samples were never fully defrosted during removal of a small section.  
7. Samples were placed in a Precellys tube with 800ul cell lysis buffer and shaken in a 
Precellys 24 tissue homogeniser. 
8. To reduce air bubble, the Precellys tubes were centrifuged in a desktop centrifuge at 
maximum speed for 5 minutes.  
9. Samples were transferred to an RNA-free container and either frozen at -80 degrees 
or immediately processed for RNA extraction. 
10. RNA extraction was undertaken using an Ambion PureLink RNA Mini Kit as per the 
manufacturer’s instruction. 
11. RNA yield was quantified using a Thermo Scientific NanoDrop spectrophotometer. 
12. RNA to cDNA conversion was done using an Applied Biosystems High Capacity RNA-
to-cDNA kit.   
13. All qPCR measurements were done in triplicate using Taqman reagents and TaqMan 
Gene Expresssion Assay primers and probes. A Life Technologies Viia 7 was used to 





5.21 Human urine CCL7 measurements 
1. Ethical permission was granted locally to collect urine from in-patients with acute 
kidney injury as well as from healthy control subjects. 
2. All samples were collected between June and October 2014.  
3. In-patients with AKI were located by specialist registrars in renal medicine at 
Addenbrooke’s Hospital, Cambridge, England. Acute kidney injury was defined as a 
serum creatinine above 120. 
4. Both a written and verbal explanation of the study was given to the patient and 
written consent was gained from each patient who partook in the study. Patients who 
were unable to fully consent, for example as a result of a recent cerebral incident, 
were not enlisted in the study.  
5. Demographic and clinical data was collected from each patient. This information 
included age, sex, ethnicity, baseline serum creatinine and urea (if available), serum 
urea and creatinine on the date of sample collection, source of urine (catheter or 
fresh sample), urine dipstick analysis, and co-morbidities.  
6. Up to 50 milliliters of urine was collected from each patient.  
7. Multiple 1-2 milliliter samples of urine were aliquoted into plastic containers and 
frozen in liquid nitrogen contains at temperatures less than -196 degrees.  
8. Samples were chosen and defrosted on the benchtop at room temperature.  
9. Samples were not diluted as there was adequate volumes for ‘neat’ analysis and 
dilution could potentially increase error in measurement.  
10. Concentrations of CCL7 were measured using a commercially available ELISA kit using 
a modified protocol as described elsewhere.  
11. The ELISA was done by Dr Alexandra Riding as these experiments were done after my 
period of funding. All other portions of this experiment including analysis were done 
by the author. 





5.22 Statistical analysis 
1. Error bars 
In most graphs shown in this thesis, errors bars represent standard error of the mean. 
In a large number of experiments, because precious human samples from diseased 
donors are processed one-by-one, it was necessary to show an error bar which would 
calculated the predicted variation of the mean from current value. Thus it seemed 
appropriate to represent this form of error.  
 
2. Sample size 
The calculation of sample size is based on a number of factors including level of 
significance sought, expected effect size, and standard deviation of the effect. As with 
many experiments, we sought a significance as indicated by a 5% chance of the null 
hypothesis being incorrectly rejected (a p value of less than 0.05), and from previous 
description of the use of FA-induced AKI anticipated that at least 6 mice per group 
would be required. However, our initial experiments demonstrated that substantially 
variability in the severity of AKI, particularly in mice which were between 20 and 25 
grams.  We therefore subsequently sought to use mice of >25g so that the variability 
within groups was reduced, allowing the use of groups of 5-6 mice.  In some cases, 
the exact effect size of interventions was unknown, for example, the impact of the 
anti-CCL7 antibody on AKI severity. This therefore required an initial smaller pilot 
experiment to determine potential effect size.   
In addition to these statistical considerations, some of the experimental 
cohort sizes were influenced by practical considerations, and supporting the 
philosophy of "The 3Rs" as promoted by the National Centre for Replacement, 
Refinement & Reduction of Animals in Research. In particular, "Reduction" refers to 
"minimising the number of animals used per experiment" (National Centre for 
Replacement 2019). If some WT or Siglec-G-/- litters contained less than 5 mice of 
one sex, we opted to utilize them for an experiment, as waiting for additional mice 
from subsequent litters would have meant the older mice were considerably heaviesr, 




would be to schedule 1 these mice because of inadequate numbers, which we did not 
feel was in keeping with the 3R ethos.  Where possible, we tried to establish breeding 
trios to increase litter number.  In experiments utilizing mice on a C57BL/6 
background, eg, uMTs, WT controls were utilized from other breeding lines, eg, cre-
negative mice. These mice would have otherwise been culled. We accept that these 
controls may not be genetically completely identical to uMT and may lead to 
variability in the data.” 
All data was analyzed on either Microsoft Excel or Graphpad Prism except 





Chapter 6: Materials1 
6.1 General materials 
Materials listed below consist of specialized apparatuses necessary for the experiments 
described previously. Generic materials, for example petri dishes, have not been included in 
the interests of space.  
 
Description  Manufacturer and 
model 
Catalogue number Notes 
Human negative B 
cell isolation kit 
MACS Miltenyi 
Biotec B cell 
Isolation Kit II 
(human) 
130-091-151  
Murine negative B 
cell isolation kit 
MACS Miltenyi 
Biotec B cell 
isolation kit (murine) 
130-090-862  
Blood collection 
tube (mouse, for cell 
analysis) 
Sarstedt Microvette 






BD Microtainer SST 
amber tubes   
364979 Other models also 
used. 
Cell counter Life Technologies 
Countess II 
 Manual counting 
also done with 
haemocytometer 
and light microscope 
                                                     
1 The materials sections contains all materials used during the PhD. A number of listed items 
may not have been used in the experiments described above. For example, materials used in 




Cell strainer Falcon 100 µm nylon 
cell strainer 
352360  





Clamps for murine 
renal pedicles 
Micro Serrefine 
straight clamps (8 
mm length)  
18055-02 These clamps were 
replaced after every 
2 to 3 experiments 




Dimethyl sulfoxide Sigma-Aldrich 276855  
Folic acid Sigma folic acid F7876-10G  
Gloves Microflex Supreno 
(predominantly) 
SU INT M  












BD Plastipak 1ml 303172  
Needle and syringe 
(for tailbleed) 
Braun Omnican 100 9151141  











qPCR machine Applied Biosystems 
ViiA7 
  
Red cell lysis solution BD FACS Lysing 
Solution 























  Produced in-house 







Sigma-Aldrich G1146 As used in 
‘complete’ RPMI 
Flow cytometry 
fixation solution  




5ml 2% sodium azide 





88-8824-00 Not intranuclear 





Foetal bovine serum 
 









  Produced in-house: 
4ml -0.5M EDTA pH 
8, 
5g BSA, 
in 1l PBS 
Phosphate-buffered 
saline 
  Produced in-house 
by the Laboratory of 
Molecular Biology 
Wortmannin Cayman Chemicals 10010591  
Normal mouse 
serum 
  Produced in-house  
96 well round 
bottom plates (Nunc 
MicroWell Plates 
with Nunclon Delta 
surface) 






6.2 Antibodies (anti-human) 
Antigen Clone Fluorochrome(s) Manufacturer Catalogue 
numbers 
CCL7  APC Miltenyi Biotec 130-105-358 
CD1d 51.1 PerCP/Cy5.5 BioLegend 350312 
CD4 OKT4 eFluor 450 eBioscience 48-0048-41 
CD5 UCHT2 APC BioLegend 300612 
CD8 RPA-T8 Brilliant violet 650 BioLegend 301041 
CD9 HI9a PE BioLegend 312106 
CD19 SJ25C1 BV786 BD Horizon 563325 
CD19 SJ25C1 BUV737 BD Horizon 564303 
CD19 HIB19 APC eFluor 780 eBioscience 47-0199-42 
CD19 HIB19 BV650 BioLegend 302238 
CD24 ML5 BV605 BD Horizon 562788 
CD24 ML5 ML5 BioLegend 311104 
CD25 BC96 PE eBioscience 12-0259-41 
CD25 BC96 APC BioLegend 302610 
CD27 L128 BUV395 BD Horizon 563816 
CD27 O323 APC/Cy7 BioLegend 302816 
CD38 HIT2 APC eBioscience 17-0389-42 
CD38 HIT2 PerCP-Cy5.5 BioLegend 303522 
CD45 2D1 APC/Cy7 BioLegend 368515 
CD45RA HI100 PerCP-Cy5.5 Invitrogen 45-0458-41 
CD122 Mik-β3 BV421 BD Horizon 562887 
CD122  PE BD Pharmigen 554525 
CD122 TU27 BV 421 BioLegend 339010 
CD122 TU27 PE BioLegend 339006 
CD127 A019D5 Alexa Fluor 647 BioLegend 351317 




CD138 DL101 PE-Cy7 eBioscience 25-1389-42 
CD197 G043H7 Brilliant violet 785 BioLegend 353229 
CXCR5 MU5UBEE FITC eBioscience 11-9185-41 
IFNγ 4S.B3 eFluor 450 eBioscience 48-7319-42 
IgD IA6-2 APC-H7 BD Pharmigen 561305 
IgM II/41 APC eBioscience 17-5790-82 
IL-10 JES5-16E3 PE BioLegend 501404 
IL-10 JES5-16E3 APC eBioscience 17-7101-82 
TIM-1 1D12 APC BioLegend 353906 






6.3 Antibodies (anti-mouse) 
Antigen Clone Fluorochrome(s) Manufacturer Catalogue 
numbers 
B220 RA3-6B2 eFluor450 eBioscience 48-0452-82 
B220 RA3-6B2 PerCP/Cy5.5 BioLegend 103236 
B220 RA3-6B2 PE-Cyanine7 eBioscience 25-0452-82 
B220 RA3-6B2 Alexa Fluor 647 BD Pharmigen 557683 
B220 RA3-6B2 APC-eFluor 780 eBioscience 47-0452-82 
CD3 17A2 Brilliant Violet 510 BioLegend 100233 
CD3 17A2 Brilliant Violet 605 BioLegend 100237 
CD3 17A2 Brilliant Violet 785 BioLegend 100231 
CD3e 145-2C11 eFluor450 eBioscience 48-0031-82 
CD3e 145-2C11 Brilliant Violet 650 BD Horizon 564378 
CD3e 145-2C11 Alexa Fluor 488 BioLegend 100321 
CD4 GK1.5 eFluor 450 eBioscience 48-0041-82 
CD4 GK1.5 FITC eBioscience 11-0041-85 
CD4 RM4-5 Brilliant Violet 605 BioLegend 100548 
CD4 GK1.5 PE eBioscience 12-0041-82 
CD4 GK1.5 PE-Cyanine7 eBioscience 25-0041-82 
CD4 GK1.5 APC-eFluor 780 eBioscience 47-0041-82 
CD5 53-7.3 APC eBioscience 17-0051-82 
CD5 53-7.3 Brilliant Violet 510 BioLegend 100627 
CD5 53-7.3 PE Invitrogen 12-0051-82 
CD8 53-6.7 eFluor 450 eBioscience 48-0081-82 
CD8a 53-6.7 FITC eBioscience 11-0081-85 
CD9 eBioKMC8 eFluor 450 eBioscience 48-0091-80 
CD9 eBioKMC8 FITC eBioscience 11-0091-82 
CD9 eBioKMC8 APC eBioscience 17-0091-82 




CD11b M1/70 eFluor 450 eBioscience 48-0112-82 
CD11b M1/70 Brilliant Violet 605 BioLegend 101237 
CD11b M1/70 Brilliant Violet 650 BioLegend 101239 
CD11b M1/70 FITC eBioscience 11-0112-85 
CD11b M1/70 PE BioLegend 101208 
CD11b M1/70 APC-eFluor 780 eBioscience 47-0112-82 
CD11c N418 eFluor 450 eBioscience 48-0114-82 
CD11c N418 FITC Tonbo 35-0114-U025 
CD11c N418 PE BioLegend 117308 
CD11c N418 PE-Cyanine7 eBioscience 25-0114-82 
CD11c N418 APC-eFluor 780 eBioscience 47-0114-82 
CD19 eBio1D3 eFluor 450 eBioscience 48-0193-82 
CD19 6D5 Brilliant violet 605 BioLegend 115540 
CD19 6D5 Brilliant violet 785 BioLegend 115543 
CD19 1D3 PerCP/Cy5.5 Tonbo 65-0193-U100 
CD19 eBio1D3 PE eBioscience 12-0193-83 
CD19 6D5 Alexa Fluor 647 BioLegend 115522 
CD19 eBio1D3 APC-eFluor 780 eBioscience 47-0193-82 
CD21/35 eBio4E3 PE eBioscience 12-0212-82 
CD23 B3B4 PE/Cy7 BioLegend 101613 
CD25 CD61.5 PerCP/Cy5.5 eBioscience 45-0251-82 
CD25 CD61.5 PE eBioscience 12-0251-83 
CD16/32 2.4G2 None BD Pharmigen 553140 
CD45 30-F11 FITC eBioscience 17-0451-85 
CD45 30-F11 APC eBioscience 17-0451-82 
CD45.1 A20 APC-eFluor 780 eBioscience 47-0453-82 
CD45.2 104 FITC BioLegend 109805 
CD45.2 104 PE-Cyanine7 eBioscience 25-0454-82 




CD122 TM-b1 FITC eBioscience 11-1222-85 
CD138 281-2 Brilliant Violet 650 BioLegend 142517 
CD138 281-2 PE/Cy7 BioLegend 142514 
CD182 SA044G4 PerCP/Cy5.5 BioLegend 149308 
CD268 eBIO7H22-
E16 
APC eBioscience 17-5943-80 
CD274 MIH5 PE eBioscience 12-5982-82 
CXCR5 L128D7 PE Biolegend 145504 
CXCR5 2G8 APC BD Pharmingen 560615 
GR-1 BM8 FITC eBioscience 11-4801-85 
GR-1 RB6-8C5 PE-Cyanine7 eBioscience 25-5931-82 
F4/80 BM8 PE-Cyanine7 eBioscience 25-4801-82 
F4/80 BM8 APC BioLegend 123116 
GM-CSF  PE BD Biosciences 554406 
GR-1 RB6-8C5 eFluor 450 eBioscience 48-5931-82 
GR-1 RB6-8C5 BV786 BD OptiBuild 740850 
GR-1 RB6-8C5 APC BioLegend 1008412 
GR-1 RB6-8C5 APC-eFluor 780 eBioscience 47-5931-82 
Granzyme-B NGZB PE eBioscience 12-8898-80 
IgA 11-44-2 PE Invitrogen 12-5994-81 
IgD 11-26c.2a AlexaFluor 488 BioLegend 405718 
IgD 11-26c FITC eBioscience 11-5993-85 
IgD 11-26c.2a PE BioLegend 405705 
IgD 11-26 APC eBioscience 17-5993-82 
IgG Polyclonal PE eBioscience 12-4010-87 
IL-6 MP5-20F3 PE eBioscience 12-7061-81 
IL-10 JES6-5H4 PE eBioscience 12-7021-81 
IL-10 JES5-16E3 Alexa Fluor 647 BioLegend 505014 




Ly6C HK1.4 APC eBioscience 17-5932-82 






6.3 Antibodies (phosphorylation) 
Antigen Clone Fluorochrome(s) Manufacturer Catalogue 
numbers 
Akt M89-61 Alexa Fluor 647 BD Phosflow 560343 






6.4 Antibodies (isotypes) 
Mouse IgG1, κ 
isotype 
X40 BUV737 BD Horizon 564299 
Mouse IgG1, κ 
isotype  
X40 BV421 BD Horizon 562438 
Mouse IgG1, κ 
isotype 
P3.6.2.8.1 eFluor 450 eBioscience 48-4714-82 
Mouse IgG1, κ 
isotype 
P3.6.2.8.1 PE eBioscience 12-4714-42 
Mouse IgG1, κ 
isotype 
P3.6.2.8.1 PE-Cyanine7 eBioscience 25-4714-42 
Mouse IgG1, κ 
isotype 
P3.6.2.8.1 APC eBioscience 17-4714-82 
Mouse IgG1, κ 
isotype 
P3.6.2.8.1 APC-eFluor 780 eBioscience 47-4714-82 
Mouse IgG1, κ 
isotype 
 FITC BD Pharmingen 550616 
Mouse IgG1, κ 
isotype 
MOPC-21 PE BioLegend 400112 
Mouse IgG1, κ 
isotype 
MOPC-21 APC BioLegend 400120 
Rat IgG2a, κ 
isotype 
RTK2758 Alexa Fluor 488 BioLegend 400525 
Rat IgG2b, κ 
isotype 
eB149/10H5 eFluor 450 eBioscience 48-4031-80 
Rat IgG2b, κ 
isotype 
eB149/10H5 FITC eBioscience 17-4031-81 
Rat IgG2b, κ 
isotype 
eB149/10H5 APC eBioscience 17-4031-82 





Rat IgG2a, κ 
isotype 
eBR2a APC eBioscience 17-4321-81 
Rat IgG2b, κ 
isotype 
eBRG1 PerCP-Cyanine 5.5 eBioscience 45-4301-80 
Rat IgG2b, κ 
isotype 
eBRG1 APC eBioscience 17-4301-81 
Rat IgG2a, κ 
isotype 





6.5 Stimuli for in vitro experiments 
Stimulus Manufacturer Catalogue number Notes 
Recombinant IL-2 
(human) 
  Kindly provided by 





Peptrotech 200-21  
Recombinant IL-21 
(murine) 
Peptrotech 210-21  
Goat Anti-Mouse 


















ODN 2395 Class C 
CpG oligonucleotide 
InvivoGen TLRL-2395  




CD40 ligand (human) 









6.6 In vitro inhibitors 
Description  Manufacturer and 
model 
Catalogue number Notes 
U0126 Sigma 19-147 MEK-1 and MEK-2 
inhibitor 




6.7 ELISA kits 
Description  Manufacturer and 
model 
Catalogue number Notes 
ELISA plates  Nunc-Immuno™ 
MicroWell™ 96 well 
solid plates 
439454  
CCL7 ELISA (human) R&D Systems DY282  
IL-6 ELISA (human) R&D Systems DY206  
IL-6 ELISA (murine) R&D Systems DY406  
IL-10 ELISA (human) R&D Systems DY217B  
IL-10 ELISA (murine) R&D Systems DY008  
Soluble CD25 
(human) 
R&D Systems DY2438  
TNF-α ELISA (human) R&D Systems DY210  
TNF-α ELISA 
(murine) 






6.8 Polymerase chain reaction 
Description  Manufacturer and 
model 















CCL7 Thermo Scientific Hs00171147_m1  
CD19 Thermo Scientific Hs01047413_g1  
CXCL2 Thermo Scientific Hs00601975_m1  
GAPDH Thermo Scientific Hs02786624_g1  
HPRT1 Thermo Scientific Hs02800695_m1  
Ccl2 Thermo Scientific Mm00441242_m1  
Ccl5 Thermo Scientific Mm01302427_m1  
Ccl7 Thermo Scientific Mm00443113_m1  




Csf2 Thermo Scientific Mm01290062_m1  
Csf3 Thermo Scientific Mm00438334_m1  
Cx3cl1 Thermo Scientific Mm00436454_m1  
Cxcl1 Thermo Scientific Mm04207460_m1  
Cxcl2 Thermo Scientific Mm00436450_m1  
Cxcl12 Thermo Scientific Mm00445553_m1  
Gapdh Thermo Scientific Mm99999915_g1  
Hprt1 Thermo Scientific Mm03024075_m1  
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